Statnews
Jun 4, 13:17
STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more
Eli Lilly is halving its originally planned investment in the production of weight loss syringes in Germany in response to a cost-cutting law
More:
STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more. Eli Lilly is halving its originally planned investment in the production of weight loss syringes in Germany in response to a cost-cutting law
TL;DR:
Eli Lilly is halving its originally planned investment in the production of weight loss syringes in Germany in response to a cost-cutting law
Endpoints
Jun 4, 13:04
Parabilis Medicines charts $413M IPO to back peptide pipeline
Parabilis Medicines, the peptide biotech led by former Johnson & Johnson R&D head Mathai Mammen, is seeking more than $400 million in its Nasdaq debut. If the drug developer follows through with its plans, that ...
More:
Parabilis Medicines charts $413M IPO to back peptide pipeline. Parabilis Medicines, the peptide biotech led by former Johnson & Johnson R&D head Mathai Mammen, is seeking more than $400 million in its Nasdaq debut. If the drug developer follows through with its plans, that ...
TL;DR:
Parabilis Medicines, the peptide biotech led by former Johnson & Johnson R&D head Mathai Mammen, is seeking more than $400 million in its Nasdaq debut.
Fiercebiotech
Jun 4, 11:44
Innovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADC
Innovent Biologics has reported a phase 3 victory for IBI343, boosting the prospects of an antibody-drug conjugate (ADC) that Takeda bet big on last year.
More:
Astellas won FDA approval for an anti-CLDN18.2 antibody in 2024. Patients had received at least two prior systemic therapies. At the first interim analysis, progression-free survival (PFS) was significantly longer on IBI343 than on investigator-selected control therapies, which included chemotherapy drugs. PFS was one of the study’s primary endpoints.
TL;DR:
Innovent Biologics has reported a phase 3 victory for IBI343, boosting the prospects of an antibody-drug conjugate (ADC) that Takeda bet big on last year.
Fiercebiotech
Jun 4, 11:33
Medline earns FDA warning letter ire for repeated toxic bacteria problems
Medical device distribution giant Medline has been slammed for a second time since April by an FDA warning letter that has chided the company for repeated problems centered on the presence of toxic bacteria in finished products.
More:
The FDA last inspected Medline’s Waukegan, Illinois, facility between October 6 through 14 last year, finding that the site failed to appropriately investigate any questionable discrepancies or failures related to its components meeting specifications. “Your investigations into contaminated drug product samples identified B. cereus contamination in your drug products.
TL;DR:
Medical device distribution giant Medline has been slammed for a second time since April by an FDA warning letter that has chided the company for repeated problems centered on the presence of toxic bacteria in finished products.
Fiercebiotech
Jun 4, 11:33
From business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’
Jun 4, 2026 8:26am Cabaletta Bio CAR-T Autoimmune Diseases lupus In the race to turn CAR-T cell therapies against autoimmune diseases, Cabaletta Bio has always been blazing its own trail.
More:
The Philadelphia-based biotech is edging closer to its ambition of submitting its autologous CD19-directed CAR-T resecabtagene autoleucel (rese-cel) for approval in the second half of next year to treat myositis, a condition characterized by inflammation of the muscles.
TL;DR:
In the race to turn CAR-T cell therapies against autoimmune diseases, Cabaletta has always been blazing its own trail.
Endpoints
Jun 4, 11:01
ADC Therapeutics' confirmatory data for Zynlonta muddied by death rates
ADC Therapeutics’ bid to secure full approval for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma has been complicated by death rates in its confirmatory trial. The company said ...
More:
ADC Ther­a­peu­tics’ bid to se­cure full ap­proval for Zyn­lon­ta in re­lapsed or re­frac­to­ry dif­fuse large B-cell lym­phoma has been com­pli­cat­ed by death rates in its … Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
TL;DR:
ADC Therapeutics’ bid to secure full approval for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma has been complicated by death rates in its confirmatory trial.
Fiercebiotech
Jun 4, 08:58
Alnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneer
Alnylam has partnered with the person who helped put the “T” in ChatGPT, paying $30 million to work with Jakob Uszkoreit’s Inceptive Nucleics on artificial intelligence-enabled drug design.
More:
Inceptive raised $120 million from backers including Nvidia across rounds in 2021 and 2023. Having used the money to apply AI to sequence-based medicines such as siRNA, Inceptive has landed a deal with a leader in its area of specialization. Inceptive has trained its models on sequence, function and structure data.
TL;DR:
Alnylam has partnered with the person who helped put the “T” in ChatGPT, paying $30 million to work with Jakob Uszkoreit’s Inceptive Nucleics on artificial intelligence-enabled drug design.
Endpoints
Jun 4, 07:00
ADC biotech Ona Therapeutics secures $86.6M in Series B raise
Barcelona-based Ona Therapeutics has raised $86.6 million in a Series B round to advance two ADC candidates into the clinic. CEO Valerie Vanhooren told Endpoints News in an interview that the cash should provide two-and-a-half ...
More:
ADC biotech Ona Therapeutics secures $86.6M in Series B raise. Barcelona-based Ona Therapeutics has raised $86.6 million in a Series B round to advance two ADC candidates into the clinic. CEO Valerie Vanhooren told Endpoints News in an interview that the cash should provide two-and-a-half ...
TL;DR:
Barcelona-based Ona Therapeutics has raised $86.6 million in a Series B round to advance two ADC candidates into the clinic.
Endpoints
Jun 3, 20:45
Alnylam to pay $30M upfront to AI startup Inceptive in RNA R&D deal
Alnylam Pharmaceuticals announced its first discovery-focused AI deal Wednesday, tapping a Silicon Valley biotech startup to see if AI can boost its R&D efforts. Alnylam and Inceptive signed a collaboration combining the Cambridge, MA-based company's ...
More:
Alnylam to pay $30M upfront to AI startup Inceptive in RNA R&D deal. Alnylam Pharmaceuticals announced its first discovery-focused AI deal Wednesday, tapping a Silicon Valley biotech startup to see if AI can boost its R&D efforts. Alnylam and Inceptive signed a collaboration combining the Cambridge, MA-based company's ...
TL;DR:
Alnylam Pharmaceuticals announced its first discovery-focused AI deal Wednesday, tapping a Silicon Valley biotech startup to see if AI can boost its R&D efforts.
Statnews
Jun 3, 20:45
STAT+: Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics
Alnylam announced a three-year deal with Inceptive Nucleics, worth up to $2 billion, with $30 million upfront in cash and equity in the startup.
More:
Jakob Uszkoreit went from inventing the “T” in ChatGPT to putting the “AI” in Alnylam’s RNAi therapeutics. After over a dozen years at Google, where he’d co-authored the seminal “Attention is all you need” paper that laid the foundations for artificial intelligence models like GPT, Uszkoreit in 2021 left a job at Google Brain to start Inceptive Nucleics.
TL;DR:
Alnylam announced a three-year deal with Inceptive Nucleics, worth up to $2 billion, with $30 million upfront in cash and equity in the startup.
Genengnews
Jun 3, 19:42
Human Hookworm Engineered to Produce, Secrete Anti-Tetrodotoxin Antibody Into Preclinical Host Bloodstream
Researchers engineered a human hookworm to produce an anti-tetrodotoxin antibody, which the parasite secreted into the bloodstream of a preclinical host animal, and which studies showed partially neutralized the toxin. The post Human Hookworm Engineered to Produce, Secrete Anti-Tetrodotoxin Antibody Into Preclinical Host Bloodstream appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Human Hookworm Engineered to Produce, Secrete Anti-Tetrodotoxin Antibody Into Preclinical Host Bloodstream. Researchers engineered a human hookworm to produce an anti-tetrodotoxin antibody, which the parasite secreted into the bloodstream of a preclinical host animal, and which studies showed partially neutralized the toxin.
TL;DR:
The post Human Hookworm Engineered to Produce, Secrete Anti-Tetrodotoxin Antibody Into Preclinical Host Bloodstream appeared first on GEN - Genetic Engineering and Biotechnology News .
Fiercebiotech
Jun 3, 19:09
Lilly, Boehringer to slash at least $1B each from planned investments in Germany
In response to a planned healthcare reform initiative in Germany that would reduce the prices of branded drugs, Eli Lilly and Boehringer Ingelheim have slashed their planned investments in the country, each by at least $1 billion.
More:
Jun 3, 2026 3:10pm Germany Eli Lilly Boehringer Ingelheim investment Eli Lilly and Boehringer Ingelheim are cutting back on planned investments in Germany in response to a new government healthcare initiative, representatives for the companies told Fierce. The cutbacks are significant. Lilly will slice its planned investment of 2.3 billion euros ($2.
TL;DR:
In response to a planned healthcare reform initiative in Germany that would reduce the prices of branded drugs, Eli Lilly and Boehringer Ingelheim have slashed their planned investments in the country, each by at least $1 billion.
Genengnews
Jun 3, 19:07
Small Molecules to Big Partnership: Incyte, Genesis Expand AI Collaboration to $1B+
Behind the expansion of their collaboration, Incyte and Genesis say, is the promise shown so far by the two initial targets, both selected by Incyte as called for in the initial strategic collaboration. One is a “very hard-to-drug, novel target” for which the companies worked to create novel, first-in-class chemical matter, while the other is a target that other companies have sought to make druggable without success, Pablo J. Cagnoni, MD, Incyte’s president and global head of R&D, told GEN . The post Small Molecules to Big Partnership: Incyte, Genesis Expand AI Collaboration to $1B+ appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Behind the expansion of their collaboration, Incyte and Genesis say, is the promise shown so far by the two initial targets, both selected by Incyte as called for in the initial strategic collaboration.
TL;DR:
The post Small Molecules to Big Partnership: Incyte, Genesis Expand AI Collaboration to $1B+ appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 3, 19:00
Cellares and TScan Agree to Evaluate Automated Manufacturing TSC-101 for Patients with Hematologic Malignancies
As TSC-101 is advanced toward a pivotal trial, which is expected to begin later this year, Cellares’ manufacturing platform is being evaluated as a scalable and economical path to future demand. The post Cellares and TScan Agree to Evaluate Automated Manufacturing TSC-101 for Patients with Hematologic Malignancies appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Cellares and TScan Agree to Evaluate Automated Manufacturing TSC-101 for Patients with Hematologic Malignancies. As TSC-101 is advanced toward a pivotal trial, which is expected to begin later this year, Cellares’ manufacturing platform is being evaluated as a scalable and economical path to future demand.
TL;DR:
The post Cellares and TScan Agree to Evaluate Automated Manufacturing TSC-101 for Patients with Hematologic Malignancies appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 3, 18:54
New Antibiotic, Manikomycin, Acts on Novel Ribosomal Target
Researchers discovered manikomycin, a novel antibiotic that kills drug-resistant bacteria by targeting a previously unknown ribosomal vulnerability. The breakthrough could lead to a new class of treatments against antimicrobial resistant bacteria. The post New Antibiotic, Manikomycin, Acts on Novel Ribosomal Target appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Researchers discovered manikomycin, a novel antibiotic that kills drug-resistant bacteria by targeting a previously unknown ribosomal vulnerability. The breakthrough could lead to a new class of treatments against antimicrobial resistant bacteria.
TL;DR:
The post New Antibiotic, Manikomycin, Acts on Novel Ribosomal Target appeared first on GEN - Genetic Engineering and Biotechnology News .
Endpoints
Jun 3, 17:58
Bristol Myers turns focus to AI costs after broad rollout to workers
PALO ALTO, CA — After giving artificial intelligence tools to thousands of employees, Bristol Myers Squibb is now working to get a handle on the costs of the technology and where it’s actually creating productivity and ...
More:
PA­LO AL­TO, CA — Af­ter giv­ing ar­ti­fi­cial in­tel­li­gence tools to thou­sands of em­ploy­ees, Bris­tol My­ers Squibb is now work­ing to get a han­dle on the costs … Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
TL;DR:
PALO ALTO, CA — After giving artificial intelligence tools to thousands of employees, Bristol Myers Squibb is now working to get a handle on the costs of the technology and where it’s actually creating productivity and ...
Endpoints
Jun 3, 17:37
Axsome pushes back generic entry for narcolepsy drug until 2040
Axsome Therapeutics has successfully delayed generic competition for its narcolepsy drug Sunosi until 2040. The company announced on Wednesday that it has reached a settlement with the last applicant looking to ...
More:
Axsome pushes back generic entry for narcolepsy drug until 2040. Axsome Therapeutics has successfully delayed generic competition for its narcolepsy drug Sunosi until 2040. The company announced on Wednesday that it has reached a settlement with the last applicant looking to ...
TL;DR:
Axsome Therapeutics has successfully delayed generic competition for its narcolepsy drug Sunosi until 2040.
Fiercebiotech
Jun 3, 17:15
Unlocking Unstructured Data with AI for Optimized Protocol Development
In this podcast, Mike Eckrote, SVP, Strategic Solutions at Advarra, talks about how artificial intelligence is being used to pull insights out of structured and unstructured data sources to help sponsors avoid protocol amendments and delays.
TL;DR:
In this podcast, Mike Eckrote, SVP, Strategic Solutions at Advarra, talks about how artificial intelligence is being used to pull insights out of structured and unstructured data sources to help sponsors avoid protocol amendments and delays.
Endpoints
Jun 3, 16:55
FDA guides pharma on explaining unapproved drugs to payors
Biopharma companies preparing to launch the next practice-changing blockbusters want payors to know what's coming before they ultimately land an FDA approval. The trick is to do that without stretching the truth and running afoul ...
More:
FDA guides pharma on explaining unapproved drugs to payors. Biopharma companies preparing to launch the next practice-changing blockbusters want payors to know what's coming before they ultimately land an FDA approval. The trick is to do that without stretching the truth and running afoul ...
TL;DR:
Biopharma companies preparing to launch the next practice-changing blockbusters want payors to know what's coming before they ultimately land an FDA approval.
Genengnews
Jun 3, 16:00
Bioproduction Pivots from Centralized to Regional Support
The global biopharma industry is placing increasing importance on regional support rather than only centralized expertise to help complex programs advance. A key benefit is access to local expertise in or near their time zone. The post Bioproduction Pivots from Centralized to Regional Support appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
The global biopharma industry is placing increasing importance on regional support rather than only centralized expertise to help complex programs advance. A key benefit is access to local expertise in or near their time zone. The post Bioproduction Pivots from Centralized to Regional Support appeared first on GEN - Genetic Engineering and Biotechnology News .
TL;DR:
The post Bioproduction Pivots from Centralized to Regional Support appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 3, 16:00
Gentler Cell Separation Methods Gain Momentum
As cell therapy developers push toward commercial-scale manufacturing, bioprocessing experts rethink how hematopoietic stem cells are isolated. Emerging buoyancy-based technologies promise higher yields, gentler handling, and scalable workflows that could reshape production of next-generation regenerative medicines. The post Gentler Cell Separation Methods Gain Momentum appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
As cell therapy developers push toward commercial-scale manufacturing, bioprocessing experts rethink how hematopoietic stem cells are isolated. Emerging buoyancy-based technologies promise higher yields, gentler handling, and scalable workflows that could reshape production of next-generation regenerative medicines.
TL;DR:
The post Gentler Cell Separation Methods Gain Momentum appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 3, 16:00
Web App Helps Flag Antibodies Where Manufacturability Might Be an Issue
A web app for analyzing antibody structure could help drug manufacturers assess the developability of their products, say researchers who have developed the therapeutic antibody profiler (TAP) and other software. The post Web App Helps Flag Antibodies Where Manufacturability Might Be an Issue appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Web App Helps Flag Antibodies Where Manufacturability Might Be an Issue. A web app for analyzing antibody structure could help drug manufacturers assess the developability of their products, say researchers who have developed the therapeutic antibody profiler (TAP) and other software.
TL;DR:
The post Web App Helps Flag Antibodies Where Manufacturability Might Be an Issue appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 3, 16:00
NIIMBL to Support Vector Production and AI-Ready Training Projects
Improved viral vector production and an AI-ready workforce are the future of the drug industry, according to NIIMBL, which has selected several AAV and AI-focused projects for support. The post NIIMBL to Support Vector Production and AI-Ready Training Projects appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
NIIMBL to Support Vector Production and AI-Ready Training Projects. Improved viral vector production and an AI-ready workforce are the future of the drug industry, according to NIIMBL, which has selected several AAV and AI-focused projects for support.
TL;DR:
The post NIIMBL to Support Vector Production and AI-Ready Training Projects appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 3, 15:28
Immune Cell Phenotyping: Cell Surface Architecture Informs Disease Biology
In this GEN webinar, Erdinc Sezgin, PhD, Karolinska Institutet, will present how his lab profiled plasma membrane order across 12 immune cell subtypes simultaneously in healthy donors and patients with long COVID and chronic lymphocytic leukemia. The post Immune Cell Phenotyping: Cell Surface Architecture Informs Disease Biology appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Immune Cell Phenotyping: Cell Surface Architecture Informs Disease Biology. In this GEN webinar, Erdinc Sezgin, PhD, Karolinska Institutet, will present how his lab profiled plasma membrane order across 12 immune cell subtypes simultaneously in healthy donors and patients with long COVID and chronic lymphocytic leukemia.
TL;DR:
The post Immune Cell Phenotyping: Cell Surface Architecture Informs Disease Biology appeared first on GEN - Genetic Engineering and Biotechnology News .
Endpoints
Jun 3, 15:24
What it will take for more employer GLP-1 coverage
Last week, Eli Lilly proclaimed that its weight loss shot and pill are now “covered for millions of Americans,” now that all three major pharmacy benefit managers have put the ...
More:
Last week, Eli Lil­ly pro­claimed that its weight loss shot and pill are now “cov­ered for mil­lions of Amer­i­cans,” now … Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
TL;DR:
Last week, Eli Lilly proclaimed that its weight loss shot and pill are now “covered for millions of Americans,” now that all three major pharmacy benefit managers have put the ...
Genengnews
Jun 3, 15:16
Immune Response Activated by RNA Splicing Opens Targeted Therapies
Researchers have uncovered a previously underappreciated mechanism, where RNA splicing plays a central role in shaping immune response. The results provide insights into immune-mediated diseases, such as rheumatoid arthritis and lupus. The post Immune Response Activated by RNA Splicing Opens Targeted Therapies appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Immune Response Activated by RNA Splicing Opens Targeted Therapies. The results provide insights into immune-mediated diseases, such as rheumatoid arthritis and lupus. The post Immune Response Activated by RNA Splicing Opens Targeted Therapies appeared first on GEN - Genetic Engineering and Biotechnology News .
TL;DR:
Researchers have uncovered a previously underappreciated mechanism, where RNA splicing plays a central role in shaping immune response.
Endpoints
Jun 3, 14:56
Regeneron doubles down on CytomX after other pharmas walked away
After losing a couple of pharma alliances in recent quarters, CytomX Therapeutics is getting a major lift from a key collaborator. Regeneron is doubling down on its partnership with the Bay Area biotech, expanding the ...
More:
Regeneron doubles down on CytomX after other pharmas walked away. After losing a couple of pharma alliances in recent quarters, CytomX Therapeutics is getting a major lift from a key collaborator. Regeneron is doubling down on its partnership with the Bay Area biotech, expanding the ...
TL;DR:
After losing a couple of pharma alliances in recent quarters, CytomX Therapeutics is getting a major lift from a key collaborator.
Genengnews
Jun 3, 14:47
Translating the Promise of AAVs: From Discovery to Delivery
This episode of GEN Live will explore the rapidly evolving field of AAV gene therapy. Leaders from clinical and translational research will discuss current advances and challenges in AAV vector development, delivery, safety, and long-term therapeutic efficacy. The post Translating the Promise of AAVs: From Discovery to Delivery appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
This episode of GEN Live will explore the rapidly evolving field of AAV gene therapy. Leaders from clinical and translational research will discuss current advances and challenges in AAV vector development, delivery, safety, and long-term therapeutic efficacy.
TL;DR:
The post Translating the Promise of AAVs: From Discovery to Delivery appeared first on GEN - Genetic Engineering and Biotechnology News .
Endpoints
Jun 3, 14:32
Mineralys makes money moves before looming hypertension approval
Mineralys Therapeutics first drew attention in 2021 with a bold bet on a new type of hypertension drug called lorundrostat. It came with a tiny $1 million upfront fee to the medicine's originator, Tanabe Pharma. ...
More:
Mineralys makes money moves before looming hypertension approval. Mineralys Therapeutics first drew attention in 2021 with a bold bet on a new type of hypertension drug called lorundrostat. It came with a tiny $1 million upfront fee to the medicine's originator, Tanabe Pharma.
TL;DR:
Mineralys Therapeutics first drew attention in 2021 with a bold bet on a new type of hypertension drug called lorundrostat.
Fiercebiotech
Jun 3, 13:14
Fierce Biotech Fundraising Tracker '26: NewLimit nabs $435M; Accro accrues $50M series C
Jun 2, 2026 10:00am biotech venture capital venture capital (VC) Venture Capital Fundraising A new year brings a fresh Fierce Biotech Fundraising Tracker designed to record the significant amount of…
More:
Jun 2, 2026 10:00am biotech venture capital venture capital (VC) Venture Capital Fundraising A new year brings a fresh Fierce Biotech Fundraising Tracker designed to record the significant amount of venture capital that flows into biopharma.
TL;DR:
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.
Fiercebiotech
Jun 3, 13:02
Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact
Regeneron has expanded its research alliance with CytomX Therapeutics, paying $37 million to work on conditionally active bispecifics against two targets and secure options on more programs. The expansion swells the potential value of the deal to about $4 billion.
More:
Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact. Regeneron has expanded its research alliance with CytomX Therapeutics, paying $37 million to work on conditionally active bispecifics against two targets and secure options on more programs. The expansion swells the potential value of the deal to about $4 billion.
TL;DR:
Regeneron has expanded its research alliance with CytomX Therapeutics, paying $37 million to work on conditionally active bispecifics against two targets and secure options on more programs.
Fiercebiotech
Jun 3, 12:04
As Akeso takes center stage at ASCO, China biotech industry cements its coming of age
In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a 100% objective response rate for a cell therapy that would become Carvykti, and single-handedly put Chinese biotech on the global map. Nearly a decade later, taking the center stage at ASCO 2026, Akeso’s ivonescimab made history by offering the first-ever Chinese data set to command a coveted spot on the plenary session.
More:
In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a 100% objective response rate for a cell therapy that would become Carvykti, and single-handedly put Chinese biotech on the global map.
TL;DR:
In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a 100% objective response rate for a cell therapy that would become Carvykti, and single-handedly put Chinese biotech on the global map.
Endpoints
Jun 3, 11:00
Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases
Last month, Ascidian Therapeutics presented the first data suggesting a new way to fix broken genes may be safe in people. Now Eli Lilly has struck a deal with the startup. Ascidian’s ...
More:
Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases. Last month, Ascidian Therapeutics presented the first data suggesting a new way to fix broken genes may be safe in people. Now Eli Lilly has struck a deal with the startup.
TL;DR:
Last month, Ascidian Therapeutics presented the first data suggesting a new way to fix broken genes may be safe in people.
Genengnews
Jun 3, 11:00
Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney Diseases
Eli Lilly has expanded its genetic medicines pipeline and capabilities, agreeing to partner with Ascidian Therapeutics to develop RNA exon editors intended to treat inherited kidney diseases, through a collaboration that could generate more than $1.9 billion for the Boston biotech. The post Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney Diseases appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney Diseases. Eli Lilly has expanded its genetic medicines pipeline and capabilities, agreeing to partner with Ascidian Therapeutics to develop RNA exon editors intended to treat inherited kidney diseases, through a collaboration that could generate more than $1.
TL;DR:
The post Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney Diseases appeared first on GEN - Genetic Engineering and Biotechnology News .
Fiercebiotech
Jun 3, 10:58
IMU Biosciences nabs $53M funding round to ‘decode’ the immune system
British medtech startup IMU Biosciences has landed a £40 million ($53 million) series A as it looks to move immune system analysis from analogue to “high definition.”
More:
Its core tech uses a blood sample to measure the immune system in high detail, combining high-fidelity multi-omic analysis with machine learning. By using a blood sample, the company asserts it can measure 100 million immune data points, “providing precise actionable insights for patients and healthcare providers.
TL;DR:
British medtech startup IMU Biosciences has landed a £40 million ($53 million) series A as it looks to move immune system analysis from analogue to “high definition.”
Fiercebiotech
Jun 3, 10:03
Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B for genetic kidney diseases
Ascidian Therapeutics and Eli Lilly have signed a research collaboration potentially worth up to $1.9 billion, giving the Big Pharma company the chance to discover and develop RNA exon editing therapeutics for genetic kidney diseases.
More:
Jun 3, 2026 7:00am Ascidian Therapeutics Eli Lilly Roche gene therapy “We can probably edit almost any gene, but that doesn’t mean we should,” Dan Rosan, chief financial and business officer of Ascidian Therapeutics, told Fierce Biotech. The deal combines Ascidian’s RNA exon editing product engine with Lilly’s genetic medicines and renal disease expertise.
TL;DR:
Ascidian Therapeutics and Eli Lilly have signed a research collaboration potentially worth up to $1.9 billion, giving the Big Pharma company the chance to discover and develop RNA exon editing therapeutics for genetic kidney diseases.
Genengnews
Jun 3, 09:00
Spatial Single‑Cell Platform Reveals Barriers to Antibody Delivery in Solid Tumors
A new single‑cell spatial pharmacobiology platform visualizes how therapeutic antibodies move through human solid tumors, revealing conserved stromal barriers that restrict delivery and target engagement. The post Spatial Single‑Cell Platform Reveals Barriers to Antibody Delivery in Solid Tumors appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Spatial Single‑Cell Platform Reveals Barriers to Antibody Delivery in Solid Tumors. A new single‑cell spatial pharmacobiology platform visualizes how therapeutic antibodies move through human solid tumors, revealing conserved stromal barriers that restrict delivery and target engagement.
TL;DR:
The post Spatial Single‑Cell Platform Reveals Barriers to Antibody Delivery in Solid Tumors appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 2, 20:27
Cross-Reactive T Cells Could Point to Broad Vaccines or Treatments for Measles, Nipah Virus
Scientists identified "cross-reactive" T cells that can recognize different paramyxovirus pathogens, which may point to the development of vaccines and therapies that can target measles, Nipah, and other paramyxovirus infections at once. The post Cross-Reactive T Cells Could Point to Broad Vaccines or Treatments for Measles, Nipah Virus appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Cross-Reactive T Cells Could Point to Broad Vaccines or Treatments for Measles, Nipah Virus. Scientists identified "cross-reactive" T cells that can recognize different paramyxovirus pathogens, which may point to the development of vaccines and therapies that can target measles, Nipah, and other paramyxovirus infections at once.
TL;DR:
The post Cross-Reactive T Cells Could Point to Broad Vaccines or Treatments for Measles, Nipah Virus appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 2, 20:26
Fulcrum Halts Development of SCD Candidate Pociredir, Sets Strategic Review
The FDA's concerns, which the agency raised with Fulcrum executives at a recent end-of-phase meeting, stemmed from an unexpectedly high rate of secondary blood cancers seen with another PRC2 inhibitor—Ipsen’s Tazverik ® (tazemetostat), indicated to treat follicular lymphoma and epithelioid sarcoma, the company disclosed, based on meeting minutes received May 28. The post Fulcrum Halts Development of SCD Candidate Pociredir, Sets Strategic Review appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Fulcrum Halts Development of SCD Candidate Pociredir, Sets Strategic Review. The FDA's concerns, which the agency raised with Fulcrum executives at a recent end-of-phase meeting, stemmed from an unexpectedly high rate of secondary blood cancers seen with another PRC2 inhibitor—Ipsen’s Tazverik ® (tazemetostat), indicated to treat follicular lymphoma and epithelioid sarcoma, th…
TL;DR:
The post Fulcrum Halts Development of SCD Candidate Pociredir, Sets Strategic Review appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 2, 19:00
Disease Detection Gets Boost from Keck’s New Brain Reference Map
A research team used diffusion magnetic resonance imaging (MRI) scans from more than 54,000 people to chart how the brain’s communication pathways develop, mature, and decline across the lifespan. The post Disease Detection Gets Boost from Keck’s New Brain Reference Map appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Disease Detection Gets Boost from Keck’s New Brain Reference Map. A research team used diffusion magnetic resonance imaging (MRI) scans from more than 54,000 people to chart how the brain’s communication pathways develop, mature, and decline across the lifespan.
TL;DR:
The post Disease Detection Gets Boost from Keck’s New Brain Reference Map appeared first on GEN - Genetic Engineering and Biotechnology News .
Endpoints
Jun 2, 17:50
Lilly gives hospitals deadline to comply with 340B claims data policy
Eli Lilly is giving a group of hospitals five days to comply with its new claims data policy or risk losing their 340B discounts. Some health centers aren’t cooperating with Lilly's recent push to fight ...
More:
Eli Lilly is giving a group of hospitals five days to comply with its new claims data policy or risk losing their 340B discounts. Some health centers aren’t cooperating with Lilly's recent push to fight ...
TL;DR:
Eli Lilly is giving a group of hospitals five days to comply with its new claims data policy or risk losing their 340B discounts.
Endpoints
Jun 2, 17:40
FDA details flexibilities for new cell and gene therapies to leverage past data
The FDA is further explaining to cell and gene therapy developers the types of prior knowledge companies can leverage for clinical, nonclinical and manufacturing-related work, according to new CBER draft guidance released Tuesday. Building off ...
More:
The FDA is fur­ther ex­plain­ing to cell and gene ther­a­py de­vel­op­ers the types of pri­or knowl­edge com­pa­nies can lever­age for clin­i­cal, non­clin­i­cal and man­u­fac­tur­ing-re­lat­ed work … Get free access to a limited number of articles, plus choose newsletters to get st…
TL;DR:
The FDA is further explaining to cell and gene therapy developers the types of prior knowledge companies can leverage for clinical, nonclinical and manufacturing-related work, according to new CBER draft guidance released Tuesday.
Endpoints
Jun 2, 17:34
Anti-aging biotech NewLimit raises $435M at $3B+ valuation
The Bay Area startup NewLimit has closed one of biotech's largest private financings of 2026 and expects to start human testing next year for its first anti-aging drug candidate. NewLimit said Tuesday it has raised ...
More:
The Bay Area start­up NewLim­it has closed one of biotech’s largest pri­vate fi­nanc­ings of 2026 and ex­pects to start hu­man test­ing next year for its … Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
TL;DR:
The Bay Area startup NewLimit has closed one of biotech's largest private financings of 2026 and expects to start human testing next year for its first anti-aging drug candidate.
Fiercebiotech
Jun 2, 16:56
Foundation Medicine tallies FDA nod to pair its blood test with Pfizer’s prostate cancer combo
Foundation Medicine tallied another nod from the FDA for one of its genomic profiling tests that searches for specific biomarkers in tumor tissue samples.
More:
This time, it's Pfizer’s prostate cancer combo Talzenna (talazoparib) and Xtandi (enzalutamide), which can identify patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), the company said in a June 1 press release.
TL;DR:
Foundation Medicine tallied another nod from the FDA for one of its genomic profiling tests that searches for specific biomarkers in tumor tissue samples.
Fiercebiotech
Jun 2, 16:45
New heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells
Anti-aging startup NewLimit is back with a fresh fundraise of $435 million after landing on its first clinic-ready candidate years earlier than expected.
More:
The series C was led by longtime supporter Founders Fund, which was joined by fellow returners like Kleiner Perkins, Eli Lilly Ventures and Human Capital alongside newcomers Thrive Capital, Greenoaks and Quiet Capital. “We started to get data that was far more compelling than we had ever expected at that point in time,” Kimmel said.
TL;DR:
Anti-aging startup NewLimit is back with a fresh fundraise of $435 million after landing on its first clinic-ready candidate years earlier than expected.
Fiercebiotech
Jun 2, 15:58
ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer
To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug giredestrant. Instead, the Swiss pharma has been inspired to open a new phase 3 study in the adjuvant setting.
More:
ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer. To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug giredestrant. Instead, the Swiss pharma has been inspired to open a new phase 3 study in the adjuvant setting.
TL;DR:
To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug giredestrant.
Statnews
Jun 2, 15:04
STAT+: Radiopharmaceutical shows promise in post-Pluvicto setting
Abivax's ulcerative colitis data, Fulcrum's scrapped sickle cell drug, and more biotech news from The Readout
TL;DR:
Abivax's ulcerative colitis data, Fulcrum's scrapped sickle cell drug, and more biotech news from The Readout
Genengnews
Jun 2, 14:36
Kinase Droplets Activate Growth Signals, Path for Cancer Therapy
Cellular phase separation, a mechanism that organizes biomolecules into dense, liquid-like condensates, may play a previously underappreciated role in regulating kinase activity, offering therapeutic applications. The post Kinase Droplets Activate Growth Signals, Path for Cancer Therapy appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Kinase Droplets Activate Growth Signals, Path for Cancer Therapy. Cellular phase separation, a mechanism that organizes biomolecules into dense, liquid-like condensates, may play a previously underappreciated role in regulating kinase activity, offering therapeutic applications.
TL;DR:
The post Kinase Droplets Activate Growth Signals, Path for Cancer Therapy appeared first on GEN - Genetic Engineering and Biotechnology News .
Endpoints
Jun 2, 13:55
Travere pays Everest $112M upfront to grow rare kidney disease pipeline
Travere Therapeutics is enlisting the help of China-based Everest Medicines to bolster its rare kidney disease pipeline beyond its approved medicine Filspari. The San Diego biotech is doling out $112 million upfront to the Shanghai ...
More:
Travere pays Everest $112M upfront to grow rare kidney disease pipeline. Travere Therapeutics is enlisting the help of China-based Everest Medicines to bolster its rare kidney disease pipeline beyond its approved medicine Filspari. The San Diego biotech is doling out $112 million upfront to the Shanghai ...
TL;DR:
Travere Therapeutics is enlisting the help of China-based Everest Medicines to bolster its rare kidney disease pipeline beyond its approved medicine Filspari.
Fiercebiotech
Jun 2, 13:47
Travere scales Everest with $1.1B deal for BTK inhibitor aimed at rare kidney diseases
Travere Therapeutics has set its sights on Everest Medicines' therapy for rare kidney diseases, handing over $112.5 million upfront for a drug that has already begun the trek into the clinic.
TL;DR:
Travere Therapeutics has set its sights on Everest Medicines' therapy for rare kidney diseases, handing over $112.5 million upfront for a drug that has already begun the trek into the clinic.
Endpoints
Jun 2, 13:31
Legend Biotech shares first in vivo CAR-T data, its next act after Carvykti
Legend Biotech’s long-awaited first showing of in vivo CAR-T data is here, fueling momentum in the growing field. Legend reported results Tuesday on 12 lymphoma patients from an investigator-initiated trial conducted in China, showing that ...
More:
Legend Biotech shares first in vivo CAR-T data, its next act after Carvykti. Legend Biotech’s long-awaited first showing of in vivo CAR-T data is here, fueling momentum in the growing field. Legend reported results Tuesday on 12 lymphoma patients from an investigator-initiated trial conducted in China, showing that ...
TL;DR:
Legend Biotech’s long-awaited first showing of in vivo CAR-T data is here, fueling momentum in the growing field.
Genengnews
Jun 2, 13:20
Low-Cost, Portable Biotech Tools Improve Access to Bioresearch and Diagnostics
Using synthetic biology and cell-free systems, paired with low-cost hardware, researchers developed a suite of low-cost, portable biotechnology tools to improve access to laboratory research and diagnostics in resource-limited settings. The post Low-Cost, Portable Biotech Tools Improve Access to Bioresearch and Diagnostics appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Low-Cost, Portable Biotech Tools Improve Access to Bioresearch and Diagnostics. Using synthetic biology and cell-free systems, paired with low-cost hardware, researchers developed a suite of low-cost, portable biotechnology tools to improve access to laboratory research and diagnostics in resource-limited settings.
TL;DR:
The post Low-Cost, Portable Biotech Tools Improve Access to Bioresearch and Diagnostics appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 2, 13:00
Circio and GenAssist Collaborate on Gene Therapy for Muscle Disease and In Vivo Cell Therapy
An official at Circio says that by integrating Circio's and GenAssist's complementary technologies, the parties aim to focus on the development of a joint next generation of AAV gene therapy candidates. The post Circio and GenAssist Collaborate on Gene Therapy for Muscle Disease and <i>In Vivo</i> Cell Therapy appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Circio and GenAssist Collaborate on Gene Therapy for Muscle Disease and In Vivo Cell Therapy. An official at Circio says that by integrating Circio's and GenAssist's complementary technologies, the parties aim to focus on the development of a joint next generation of AAV gene therapy candidates.
TL;DR:
The post Circio and GenAssist Collaborate on Gene Therapy for Muscle Disease and <i>In Vivo</i> Cell Therapy appeared first on GEN - Genetic Engineering and Biotechnology News .
Fiercebiotech
Jun 2, 12:11
Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks
Fulcrum Therapeutics has scrapped its sole clinical-stage program after the FDA took a hard line on the modality following the recent withdrawal of Ipsen’s Tazverik from the U.S. market.
TL;DR:
Fulcrum Therapeutics has scrapped its sole clinical-stage program after the FDA took a hard line on the modality following the recent withdrawal of Ipsen’s Tazverik from the U.S.
Fiercebiotech
Jun 2, 12:11
ASCO: Cardiff posts updated colorectal cancer data ahead of pivotal push
Cardiff Oncology has shared updated results from its phase 2 colorectal cancer trial, revealing that the study drug has yet to reach the median progression-free survival as the biotech prepares to enter pivotal development.
TL;DR:
Cardiff Oncology has shared updated results from its phase 2 colorectal cancer trial, revealing that the study drug has yet to reach the median progression-free survival as the biotech prepares to enter pivotal development.
Endpoints
Jun 2, 12:01
#ASCO26: Celcuity plans another FDA filing after positive breast cancer readout
Celcuity said a combination regimen with its experimental drug gedatolisib doubled patients' likelihood of survival without disease progression or death in a late-stage breast cancer trial. Executives shared details on Tuesday at this year's American ...
More:
#ASCO26: Celcuity plans another FDA filing after positive breast cancer readout. Celcuity said a combination regimen with its experimental drug gedatolisib doubled patients' likelihood of survival without disease progression or death in a late-stage breast cancer trial. Executives shared details on Tuesday at this year's American ...
TL;DR:
Celcuity said a combination regimen with its experimental drug gedatolisib doubled patients' likelihood of survival without disease progression or death in a late-stage breast cancer trial.
Endpoints
Jun 2, 12:00
Citing 'dangerous deals,' lawmakers propose China restrictions
A bipartisan group of Michigan lawmakers released a new bill that could greatly stifle the booming cross-border deals spree between Chinese and American biotechs. Rep. John Moolenaar (R-MI) and Rep. Debbie Dingell (D-MI) on Tuesday ...
More:
Citing 'dangerous deals,' lawmakers propose China restrictions. John Moolenaar (R-MI) and Rep. Debbie Dingell (D-MI) on Tuesday ...
TL;DR:
A bipartisan group of Michigan lawmakers released a new bill that could greatly stifle the booming cross-border deals spree between Chinese and American biotechs.
Endpoints
Jun 2, 12:00
#ASCO26: Roche details narrow failure of breast cancer pill trial
Back in March, Roche revealed that the breast cancer pill on which it had pinned billion-dollar sales expectations had failed in a pivotal Phase 3 trial. Data presented Tuesday at ASCO reveal ...
More:
Back in March, Roche revealed that the breast cancer pill on which it had pinned billion-dollar sales expectations had failed in a pivotal Phase 3 trial. Data presented Tuesday at ASCO reveal ...
TL;DR:
Back in March, Roche revealed that the breast cancer pill on which it had pinned billion-dollar sales expectations had failed in a pivotal Phase 3 trial.
Fiercebiotech
Jun 2, 11:29
MindMaze Therapeutics culls program, ends legacy ops from Relief merger to cut costs
Digital therapeutics specialist MindMaze Therapeutics is selling off a pipeline program whilst also removing all non-neurology legacy operations from its recent merger with Relief Therapeutics.
TL;DR:
Digital therapeutics specialist MindMaze Therapeutics is selling off a pipeline program whilst also removing all non-neurology legacy operations from its recent merger with Relief Therapeutics.
Endpoints
Jun 2, 11:21
Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit
Fulcrum Therapeutics is scrapping its sole clinical-stage medicine after feedback from the FDA that referenced a recently pulled cancer drug from Ipsen. Fulcrum had planned to enter a registrational trial for ...
More:
Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit. Fulcrum Therapeutics is scrapping its sole clinical-stage medicine after feedback from the FDA that referenced a recently pulled cancer drug from Ipsen. Fulcrum had planned to enter a registrational trial for ...
TL;DR:
Fulcrum Therapeutics is scrapping its sole clinical-stage medicine after feedback from the FDA that referenced a recently pulled cancer drug from Ipsen.
Fiercebiotech
Jun 2, 11:08
ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
The first-in-class EGFRxHER3 bispecific ADC that BMS paid $800 million for has shown strong phase 3 results from China that suggest it could put up a fight against blockbuster TROP2 agents in triple-negative breast cancer.
TL;DR:
The first-in-class EGFRxHER3 bispecific ADC that BMS paid $800 million for has shown strong phase 3 results from China that suggest it could put up a fight against blockbuster TROP2 agents in triple-negative breast cancer.
Fiercebiotech
Jun 2, 11:08
ASCO: Celcuity dares to dream of becoming $10B company after breast cancer win over Piqray
While Revolution Medicines dominated this year’s American Society of Clinical Oncology annual meeting by conquering the “undruggable” RAS pathway, another up-and-coming biotech hopes to do the same with a different vexing target that drives a plethora of cancers.
TL;DR:
While Revolution Medicines dominated this year’s American Society of Clinical Oncology annual meeting by conquering the “undruggable” RAS pathway, another up-and-coming biotech hopes to do the same with a different vexing target that drives a plethora of cancers.
Endpoints
Jun 2, 10:58
Cancer cases weigh down Abivax’s Phase 3 maintenance data in ulcerative colitis
Abivax has proclaimed that its maintenance trial in ulcerative colitis delivered “landmark” results, and the drug's safety profile has previously been one of its main potential selling points. But Wall Street was rattled by malignancy ...
More:
Abivax has proclaimed that its maintenance trial in ulcerative colitis delivered “landmark” results, and the drug's safety profile has previously been one of its main potential selling points. But Wall Street was rattled by malignancy ...
TL;DR:
Abivax has proclaimed that its maintenance trial in ulcerative colitis delivered “landmark” results, and the drug's safety profile has previously been one of its main potential selling points.
Endpoints
Jun 2, 10:31
Praxis sinks on late-stage study fail for seizure pill, halts second trial
Praxis Precision Medicines has had a decent run over the past eight months or so, with two major clinical wins. But on Monday, the company disclosed a late-stage failure for its investigational seizure medicine, and ...
More:
Praxis sinks on late-stage study fail for seizure pill, halts second trial. Praxis Precision Medicines has had a decent run over the past eight months or so, with two major clinical wins. But on Monday, the company disclosed a late-stage failure for its investigational seizure medicine, and ...
TL;DR:
Praxis Precision Medicines has had a decent run over the past eight months or so, with two major clinical wins.
Fiercebiotech
Jun 2, 09:01
Praxis pauses one of its seizure programs after phase 2 fail
Praxis Precision Medicines’ epilepsy pipeline has suffered a setback after a next-gen NaV blocker failed to sufficiently reduce seizures in a phase 2/3 study.
TL;DR:
Praxis Precision Medicines’ epilepsy pipeline has suffered a setback after a next-gen NaV blocker failed to sufficiently reduce seizures in a phase 2/3 study.
Endpoints
Jun 2, 09:00
Updated: Allen Institute launches $400M effort to turn brain atlas lessons into medicines
A Seattle-based nonprofit known for basic brain research is launching a $400 million initiative to translate its knowledge into drug development for neurodegenerative diseases, including Alzheimer's. It's a major new direction for the Allen Institute ...
More:
Updated: Allen Institute launches $400M effort to turn brain atlas lessons into medicines. A Seattle-based nonprofit known for basic brain research is launching a $400 million initiative to translate its knowledge into drug development for neurodegenerative diseases, including Alzheimer's. It's a major new direction for the Allen Institute ...
TL;DR:
A Seattle-based nonprofit known for basic brain research is launching a $400 million initiative to translate its knowledge into drug development for neurodegenerative diseases, including Alzheimer's.
Fiercebiotech
Jun 2, 08:41
Abivax stock suffers as cancer cases overshadow stellar efficacy in ulcerative colitis phase 3 trial
Abivax has raised the efficacy bar in ulcerative colitis, linking obefazimod to a 40%, placebo-adjusted jump in clinical remission rates in a phase 3 trial. But the share price of the biotech, a reported takeover target for several Big Pharmas, collapsed after several patients on the high dose developed cancers.
More:
Abivax has raised the efficacy bar in ulcerative colitis, linking obefazimod to a 40%, placebo-adjusted jump in clinical remission rates in a phase 3 trial. But the share price of the biotech, a reported takeover target for several Big Pharmas, collapsed after several patients on the high dose developed cancers.
TL;DR:
Abivax has raised the efficacy bar in ulcerative colitis, linking obefazimod to a 40%, placebo-adjusted jump in clinical remission rates in a phase 3 trial.
Fiercebiotech
Jun 2, 07:38
ASCO: Takeda touts ‘tremendous potential’ of Innovent’s PD-1/IL-2 bispecific after seeing survival data
Takeda and Innovent's long-term follow-up data from an early study of their collaborative PD-1/IL-2 bispecific colors the "tremendous potential" of the asset, Takeda's P.K. Morrow said in an interview.
TL;DR:
Takeda and Innovent's long-term follow-up data from an early study of their collaborative PD-1/IL-2 bispecific colors the "tremendous potential" of the asset, Takeda's P.K.
Genengnews
Jun 2, 00:15
Bio-IT World Keynote Highlights Collaborative Intelligence in AI-Driven Drug Discovery
At the meeting, experts discussed the growing need for federated learning frameworks that enable AI model training across proprietary biopharma datasets without compromising intellectual property or sensitive research data. The post Bio-IT World Keynote Highlights Collaborative Intelligence in AI-Driven Drug Discovery appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Bio-IT World Keynote Highlights Collaborative Intelligence in AI-Driven Drug Discovery. At the meeting, experts discussed the growing need for federated learning frameworks that enable AI model training across proprietary biopharma datasets without compromising intellectual property or sensitive research data.
TL;DR:
The post Bio-IT World Keynote Highlights Collaborative Intelligence in AI-Driven Drug Discovery appeared first on GEN - Genetic Engineering and Biotechnology News .
Fiercebiotech
Jun 1, 19:41
Lilly locks in 5-program R&D pact with China’s Haisco worth up to $3B, but targets unclear
Within hours of securing a gastrointestinal drug from Korea’s Hanmi Pharma, Eli Lilly has ramped up the biobucks for a wider-ranging pact with China’s Haisco Pharmaceutical.
TL;DR:
Within hours of securing a gastrointestinal drug from Korea’s Hanmi Pharma, Eli Lilly has ramped up the biobucks for a wider-ranging pact with China’s Haisco Pharmaceutical.
Genengnews
Jun 1, 19:26
Attacking Gout: Crystalys Sees Room for Its Dotinurad and Other Allopurinol Alternatives
First-patient dosing in AMETHYST comes five days after a Crystalys rival, Swedish Orphan Biovitrum (Sobi), announced positive Phase III data for pozdeutinurad, a treatment for progressive gout which like dotinurad is a next-generation, once-daily oral URAT1 inhibitor. The post Attacking Gout: Crystalys Sees Room for Its Dotinurad and Other Allopurinol Alternatives appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Attacking Gout: Crystalys Sees Room for Its Dotinurad and Other Allopurinol Alternatives. First-patient dosing in AMETHYST comes five days after a Crystalys rival, Swedish Orphan Biovitrum (Sobi), announced positive Phase III data for pozdeutinurad, a treatment for progressive gout which like dotinurad is a next-generation, once-daily oral URAT1 inhibitor.
TL;DR:
The post Attacking Gout: Crystalys Sees Room for Its Dotinurad and Other Allopurinol Alternatives appeared first on GEN - Genetic Engineering and Biotechnology News .
Fiercebiotech
Jun 1, 19:17
ASCO: Telix tees up pivotal test for Pluvicto challenger while eyeing ‘white space’ on radiopharma canvas
David Cade, the chief medical officer of Melbourne-based Telix Pharmaceuticals, traveled a long way to the American Society of Clinical Oncology meeting in Chicago with a singular goal in mind: spread the word about Telix’s pivotal trial for a potential challenger to Novartis’ Pluvicto.
TL;DR:
David Cade, the chief medical officer of Melbourne-based Telix Pharmaceuticals, traveled a long way to the American Society of Clinical Oncology meeting in Chicago with a singular goal in mind: spread the word about Telix’s pivotal trial for a potential challenger to Novartis’ Pluvicto.
Fiercebiotech
Jun 1, 19:08
At ASCO 2026, a ‘paradigm shift’ for a rare gut cancer looms
For patients with a rare cancer that arises in the gut wall, standard treatment hasn’t changed in the last 20 years. At the American Society of Clinical Oncology meeting in Chicago, GSK shared a first look at its attempt to change that.
More:
At ASCO 2026, a ‘paradigm shift’ for a rare gut cancer looms. For patients with a rare cancer that arises in the gut wall, standard treatment hasn’t changed in the last 20 years. At the American Society of Clinical Oncology meeting in Chicago, GSK shared a first look at its attempt to change that.
TL;DR:
For patients with a rare cancer that arises in the gut wall, standard treatment hasn’t changed in the last 20 years.
Endpoints
Jun 1, 18:58
The cost of a PRV is twice as high as it was three years ago — and it’s likely to stay that way
How much is a regulatory shortcut worth? The cost of a priority review voucher, which shortens the FDA’s standard review time by about four months, has roughly doubled in the last few years. The FDA ...
More:
The cost of a PRV is twice as high as it was three years ago — and it’s likely to stay that way . How much is a regulatory shortcut worth? The cost of a priority review voucher, which shortens the FDA’s standard review time by about four months, has roughly doubled in the last few years.
TL;DR:
The cost of a priority review voucher, which shortens the FDA’s standard review time by about four months, has roughly doubled in the last few years.
Endpoints
Jun 1, 18:48
Epigenetic editing shows promise against chronic hep B infections
A new method of CRISPR-based gene editing shows promise in curtailing chronic hepatitis B infections. Its twist is to silence disease-causing genes without altering the underlying DNA. Tune Therapeutics said the therapy showed some evidence ...
More:
Epigenetic editing shows promise against chronic hep B infections. Its twist is to silence disease-causing genes without altering the underlying DNA. Tune Therapeutics said the therapy showed some evidence ...
TL;DR:
A new method of CRISPR-based gene editing shows promise in curtailing chronic hepatitis B infections.
Genengnews
Jun 1, 18:26
Neuropixels Opto Integrates Electrophysiology and Optogenetics to Probe Neuronal Function
Neuropixels Opto is a single brain probe combining electrophysiology and optogenetics that simultaneously records and controls neurons deep in the brain, enabling unprecedented insights into neural circuits and brain function. The post Neuropixels Opto Integrates Electrophysiology and Optogenetics to Probe Neuronal Function appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Neuropixels Opto Integrates Electrophysiology and Optogenetics to Probe Neuronal Function. Neuropixels Opto is a single brain probe combining electrophysiology and optogenetics that simultaneously records and controls neurons deep in the brain, enabling unprecedented insights into neural circuits and brain function.
TL;DR:
The post Neuropixels Opto Integrates Electrophysiology and Optogenetics to Probe Neuronal Function appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 1, 17:48
Turning the Patent Cliff into a Bioplant Opportunity
Using duckweed as an alternative to mammalian expression systems can ease manufacturers’ transition from blockbuster to biosimilar. The post Turning the Patent Cliff into a Bioplant Opportunity appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Turning the Patent Cliff into a Bioplant Opportunity. Using duckweed as an alternative to mammalian expression systems can ease manufacturers’ transition from blockbuster to biosimilar. The post Turning the Patent Cliff into a Bioplant Opportunity appeared first on GEN - Genetic Engineering and Biotechnology News .
TL;DR:
The post Turning the Patent Cliff into a Bioplant Opportunity appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 1, 17:35
Top 10 U.S. Biopharma Clusters 2026
Mid-cap buyers, improved capital raising climate, and reshoring of manufacturing are shaping how much and where biopharmas choose to grow. The post Top 10 U.S. Biopharma Clusters 2026 appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Mid-cap buyers, improved capital raising climate, and reshoring of manufacturing are shaping how much and where biopharmas choose to grow. The post Top 10 U.S. Biopharma Clusters 2026 appeared first on GEN - Genetic Engineering and Biotechnology News .
TL;DR:
Biopharma Clusters 2026 appeared first on GEN - Genetic Engineering and Biotechnology News .
Fiercebiotech
Jun 1, 17:11
ASCO, Ryght AI team up for breast cancer trial site selection
The American Society of Clinical Oncology (ASCO) and Ryght AI are teaming up to identify research sites for an ASCO clinical trial evaluating starting doses of CDK4/6 inhibitors in patients with metastatic breast cancer.
TL;DR:
The American Society of Clinical Oncology (ASCO) and Ryght AI are teaming up to identify research sites for an ASCO clinical trial evaluating starting doses of CDK4/6 inhibitors in patients with metastatic breast cancer.
Endpoints
Jun 1, 16:50
Shionogi wins US approval for first pill to prevent Covid following exposure
Japan's Shionogi on Monday said it won FDA approval for its oral antiviral to prevent Covid‑19 in adults and children older than 12 years who have been in contact with someone ...
TL;DR:
Japan's Shionogi on Monday said it won FDA approval for its oral antiviral to prevent Covid‑19 in adults and children older than 12 years who have been in contact with someone ...
Genengnews
Jun 1, 16:37
Pharma’s Trial Problem: Outdated Systems, Broken Data, and the Coming AI Reset
In this thought leadership article, Erik Terjesen of Silicon Foundry explores how AI has the potential to transform clinical trials, while outdated data systems continue to limit progress. Although AI can help shorten timelines and improve decision-making, it is not a cure-all—it cannot fix flawed trial design, replace human oversight, or remove the need for regulatory rigor. The post Pharma’s Trial Problem: Outdated Systems, Broken Data, and the Coming AI Reset appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
In this thought leadership article, Erik Terjesen of Silicon Foundry explores how AI has the potential to transform clinical trials, while outdated data systems continue to limit progress. Although AI can help shorten timelines and improve decision-making, it is not a cure-all—it cannot fix flawed trial design, replace human oversight, or remove the need for regulatory rigor.
TL;DR:
The post Pharma’s Trial Problem: Outdated Systems, Broken Data, and the Coming AI Reset appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 1, 16:30
Targeted Protein Degradation Broadens Its Scope
Representation of the crystal structure of Sortilin extracellular domain (green surface view) in complex with a TNFα-targeting SORTAC (orange sticks).
More:
Targeted Protein Degradation Broadens Its Scope. This network governs protein homeostasis, including the synthesis, folding, trafficking, and ultimately the clearance of proteins. When these processes fail, aberrant or misfolded proteins can accumulate and drive disease.
TL;DR:
Targeted protein degradation (TPD) therapeutics seek to harness this intrinsic quality control machinery to selectively eliminate disease-causing proteins.
Genengnews
Jun 1, 16:13
Organ Chips Move Towards Mainstream Drug Development, with Hurdles Ahead
From spaceflight to high-throughput studies, evidence supports greater use of organ chips, but regulatory ambiguity and reliance on animal models slow adoption . The post Organ Chips Move Towards Mainstream Drug Development, with Hurdles Ahead appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Organ Chips Move Towards Mainstream Drug Development, with Hurdles Ahead. From spaceflight to high-throughput studies, evidence supports greater use of organ chips, but regulatory ambiguity and reliance on animal models slow adoption .
TL;DR:
The post Organ Chips Move Towards Mainstream Drug Development, with Hurdles Ahead appeared first on GEN - Genetic Engineering and Biotechnology News .
Endpoints
Jun 1, 15:58
#ASCO: Lilly's plenaries; Incyte's frontline data in lymphoma
Two plenaries related to Lilly: Researchers detailed findings from an investigator-sponsored trial using Lilly’s CDK4/6 inhibitor Verzenio in a rare cancer called dedifferentiated liposarcoma, showing it extended progression-free survival by roughly eight months compared to ...
TL;DR:
Two plenaries related to Lilly: Researchers detailed findings from an investigator-sponsored trial using Lilly’s CDK4/6 inhibitor Verzenio in a rare cancer called dedifferentiated liposarcoma, showing it extended progression-free survival by roughly eight months compared to ...
Genengnews
Jun 1, 15:58
State of the Diagnostic Industry: Recombinants on the Rise
In this June issue Thought Leader article, David A. George of Scripps Laboratories explains why recombinant technologies are the most responsible path to ensuring the continued availability of the tests patients and clinicians rely on every day. The post State of the Diagnostic Industry: Recombinants on the Rise appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
In this June issue Thought Leader article, David A. George of Scripps Laboratories explains why recombinant technologies are the most responsible path to ensuring the continued availability of the tests patients and clinicians rely on every day.
TL;DR:
The post State of the Diagnostic Industry: Recombinants on the Rise appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 1, 15:27
Next Generation Biopharma Innovation
In a quest to provide more relevant translational data, traditional in vivo models join forces with new approach methodologies. The post Next Generation Biopharma Innovation appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Next Generation Biopharma Innovation. In a quest to provide more relevant translational data, traditional in vivo models join forces with new approach methodologies. The post Next Generation Biopharma Innovation appeared first on GEN - Genetic Engineering and Biotechnology News .
TL;DR:
The post Next Generation Biopharma Innovation appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 1, 15:13
The Confidence Gap: Why Drug Discovery’s Data Explosion Hasn’t Solved Its Billion-Dollar Decision Problem
In this thought leader piece Laurence Arnold, PhD, head of R&D at Pelago Bioscience, discusses prioritizing proof over progress, so decision-makers can fail faster–and smarter. Many failures were avoidable earlier. Hard-working teams just didn't have data that would let them make the call with confidence when it mattered most, before massive resources were committed. The post The Confidence Gap: Why Drug Discovery’s Data Explosion Hasn’t Solved Its Billion-Dollar Decision Problem appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
The Confidence Gap: Why Drug Discovery’s Data Explosion Hasn’t Solved Its Billion-Dollar Decision Problem. Hard-working teams just didn't have data that would let them make the call with confidence when it mattered most, before massive resources were committed.
TL;DR:
The post The Confidence Gap: Why Drug Discovery’s Data Explosion Hasn’t Solved Its Billion-Dollar Decision Problem appeared first on GEN - Genetic Engineering and Biotechnology News .
Endpoints
Jun 1, 14:39
Agios licenses Oscotec drug; CEPI funds three potential Ebola vaccines
🪪 Agios licenses Oscotec’s immune thrombocytopenia drug: Agios is paying $25 million upfront for exclusive global rights to Oscotec’s next-generation SYK inhibitor, called cevidoplenib. The South Korean biotech is eligible ...
More:
🪪 Agios licenses Oscotec’s immune thrombocytopenia drug: Agios is paying $25 million upfront for exclusive global rights to Oscotec’s next-generation SYK inhibitor, called cevidoplenib. The South Korean biotech is eligible ...
TL;DR:
🪪 Agios licenses Oscotec’s immune thrombocytopenia drug: Agios is paying $25 million upfront for exclusive global rights to Oscotec’s next-generation SYK inhibitor, called cevidoplenib.
Endpoints
Jun 1, 14:29
#ASCO26: Kelonia Therapeutics delivers an impressive in vivo CAR-T update
CHICAGO — Eli Lilly in April penned an up to $7 billion deal to buy Kelonia Therapeutics, and now we know why. All 18 multiple myeloma patients who have received Kelonia’s in vivo CAR-T therapy ...
More:
#ASCO26: Kelonia Therapeutics delivers an impressive in vivo CAR-T update. CHICAGO — Eli Lilly in April penned an up to $7 billion deal to buy Kelonia Therapeutics, and now we know why. All 18 multiple myeloma patients who have received Kelonia’s in vivo CAR-T therapy ...
TL;DR:
CHICAGO — Eli Lilly in April penned an up to $7 billion deal to buy Kelonia Therapeutics, and now we know why.
Genengnews
Jun 1, 14:27
Novel Therapeutic Modalities Target the Undruggable
Macrocycles, de novo antibodies, and mRNA therapies are expanding the drug discovery toolbox for unmet patient needs. The post Novel Therapeutic Modalities Target the Undruggable appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Novel Therapeutic Modalities Target the Undruggable. Macrocycles, de novo antibodies, and mRNA therapies are expanding the drug discovery toolbox for unmet patient needs. The post Novel Therapeutic Modalities Target the Undruggable appeared first on GEN - Genetic Engineering and Biotechnology News .
TL;DR:
The post Novel Therapeutic Modalities Target the Undruggable appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 1, 14:16
Mass Spectrometry’s Discovery Revolution
Next-generation MS platforms are transforming drug discovery by revealing complex biology earlier, faster, and at unprecedented depth. The post Mass Spectrometry’s Discovery Revolution appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Mass Spectrometry’s Discovery Revolution. Next-generation MS platforms are transforming drug discovery by revealing complex biology earlier, faster, and at unprecedented depth. The post Mass Spectrometry’s Discovery Revolution appeared first on GEN - Genetic Engineering and Biotechnology News .
TL;DR:
The post Mass Spectrometry’s Discovery Revolution appeared first on GEN - Genetic Engineering and Biotechnology News .
Endpoints
Jun 1, 14:11
After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing
Avenzo Therapeutics, one of the first biotechs to get major Western VC backing to in-license Chinese assets, will go public in a reverse merger with Rallybio. The Monday morning deal comes ...
More:
After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing. Avenzo Therapeutics, one of the first biotechs to get major Western VC backing to in-license Chinese assets, will go public in a reverse merger with Rallybio. The Monday morning deal comes ...
TL;DR:
Avenzo Therapeutics, one of the first biotechs to get major Western VC backing to in-license Chinese assets, will go public in a reverse merger with Rallybio.
Genengnews
Jun 1, 14:08
Macrocyclic Peptide Drugs Unlocked, Membrane Permeability Screened at Scale
A new method screens large libraries of synthetic cyclic peptides to identify compounds that can enter cells for therapeutic effect, opening avenues for a modality that combines the properties of a biologic in a pill. The post Macrocyclic Peptide Drugs Unlocked, Membrane Permeability Screened at Scale appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Macrocyclic Peptide Drugs Unlocked, Membrane Permeability Screened at Scale. A new method screens large libraries of synthetic cyclic peptides to identify compounds that can enter cells for therapeutic effect, opening avenues for a modality that combines the properties of a biologic in a pill.
TL;DR:
The post Macrocyclic Peptide Drugs Unlocked, Membrane Permeability Screened at Scale appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 1, 13:49
Multiomics Mass Spec Workflows in Drug Discovery
Advances in end-to-end multiomics platforms and the underlying scientific knowledge now enable faster and more precise biomarker discovery, mechanistic insight generation, and therapeutic design—core drivers of modern drug discovery programs. The post Multiomics Mass Spec Workflows in Drug Discovery appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Multiomics Mass Spec Workflows in Drug Discovery. Advances in end-to-end multiomics platforms and the underlying scientific knowledge now enable faster and more precise biomarker discovery, mechanistic insight generation, and therapeutic design—core drivers of modern drug discovery programs.
TL;DR:
The post Multiomics Mass Spec Workflows in Drug Discovery appeared first on GEN - Genetic Engineering and Biotechnology News .
Endpoints
Jun 1, 12:51
Turn Therapeutics' eczema drug shows rapid response in mid-stage data
California biotech Turn Therapeutics shared Phase 2 data for its topical atopic dermatitis treatment that show patients experienced symptom improvement faster than usual. In an interim analysis of 50 patients, almost ...
More:
Turn Therapeutics' eczema drug shows rapid response in mid-stage data. California biotech Turn Therapeutics shared Phase 2 data for its topical atopic dermatitis treatment that show patients experienced symptom improvement faster than usual. In an interim analysis of 50 patients, almost ...
TL;DR:
California biotech Turn Therapeutics shared Phase 2 data for its topical atopic dermatitis treatment that show patients experienced symptom improvement faster than usual.
Fiercebiotech
Jun 1, 12:42
Rallybio swerves past Candid pothole to land deal with cancer drug developer Avenzo
Rallybio has steered its way to a new reverse merger, inking a deal with Avenzo Therapeutics weeks after a UCB buyout took its former partner off the market.
TL;DR:
Rallybio has steered its way to a new reverse merger, inking a deal with Avenzo Therapeutics weeks after a UCB buyout took its former partner off the market.
Fiercebiotech
Jun 1, 12:42
Agios signs $165M deal for blood disorder drug from Korea’s Oscotec that flunked phase 2 study
Days after its lead clinical-stage asset suffered a setback, Agios Pharmaceuticals has rebounded by buying a blood disorder drug that flunked a phase 2 study.
TL;DR:
Days after its lead clinical-stage asset suffered a setback, Agios Pharmaceuticals has rebounded by buying a blood disorder drug that flunked a phase 2 study.
Endpoints
Jun 1, 12:31
Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assets
Servier will pick up the muscular dystrophy business from Edgewise Therapeutics for $1.55 billion upfront, giving the French pharma company access to an experimental neuromuscular medicine that could have pivotal data by year's end. The ...
TL;DR:
Servier will pick up the muscular dystrophy business from Edgewise Therapeutics for $1.55 billion upfront, giving the French pharma company access to an experimental neuromuscular medicine that could have pivotal data by year's end.
Endpoints
Jun 1, 12:00
#ASCO26: AstraZeneca's triplet combo succeeds in liver cancer subgroup
CHICAGO — AstraZeneca on Monday reported data from a new study showing the combination of a targeted treatment and two immunotherapies can benefit patients with certain kinds of liver cancer. Individuals who received a standard procedure ...
More:
CHICAGO — AstraZeneca on Monday reported data from a new study showing the combination of a targeted treatment and two immunotherapies can benefit patients with certain kinds of liver cancer. Individuals who received a standard procedure ...
TL;DR:
CHICAGO — AstraZeneca on Monday reported data from a new study showing the combination of a targeted treatment and two immunotherapies can benefit patients with certain kinds of liver cancer.
Fiercebiotech
Jun 1, 11:05
Entry Japan with Clarity, Execute with Confidence
For biopharmaceutical companies, Japan is one of the world’s most important markets, but also among the most operationally complex. Many therapies with strong global clinical validation still face significant barriers to successful market entry, not due to scientific limitations, but because regulatory strategy, operational readiness, supply planning, and commercialization are not aligned early in the process. Although regulatory planning, business operations preparation, and supply planning are closely interconnected, they are often managed separately. This fragmented approach increases execution risk, delays timelines, and reduces the feasibility of market entry. PATH Solution was developed to address this gap by integrating these critical elements from the outset. It provides an end to end, execution focused framework spanning market feasibility and regulatory strategy through approval, launch, stable supply, and post launch operations. By aligning strategic planning with operational realities early, PATH Solution improves transparency, reduces uncertainty, and supports sustainable market access and long term value creation for biopharmaceutical companies and investors.
More:
This fragmented approach increases execution risk, delays timelines, and reduces the feasibility of market entry. It provides an end to end, execution focused framework spanning market feasibility and regulatory strategy through approval, launch, stable supply, and post launch operations.
TL;DR:
For biopharmaceutical companies, Japan is one of the world’s most important markets, but also among the most operationally complex.
Genengnews
Jun 1, 10:57
One Antibody, Fewer Scientific Surprises
Why maintaining translational continuity across preclinical research models can make or break confidence in experimental results. The post One Antibody, Fewer Scientific Surprises appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
One Antibody, Fewer Scientific Surprises. Why maintaining translational continuity across preclinical research models can make or break confidence in experimental results. The post One Antibody, Fewer Scientific Surprises appeared first on GEN - Genetic Engineering and Biotechnology News .
TL;DR:
The post One Antibody, Fewer Scientific Surprises appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 1, 10:57
Illuminating the Drug Development Path with Cell-Based Reporter Assays
In early discovery, researchers use high-throughput screening (HTS) to identify active compounds in a biologically relevant context. During lead characterization and validation, these assays generate reproducible, quantitative data to confirm activity and support candidate selection. In later stages, cell based assays are commonly used as potency assays to ensure reliability, consistency, and lot-to-lot comparability of biologics, supporting regulatory compliance. The post Illuminating the Drug Development Path with Cell-Based Reporter Assays appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
During lead characterization and validation, these assays generate reproducible, quantitative data to confirm activity and support candidate selection. In later stages, cell based assays are commonly used as potency assays to ensure reliability, consistency, and lot-to-lot comparability of biologics, supporting regulatory compliance.
TL;DR:
The post Illuminating the Drug Development Path with Cell-Based Reporter Assays appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 1, 10:56
From Discovery to Development in Emerging Modalities
ProBio is building flexible platforms for multispecific antibodies, ADCs, and other advanced therapeutic approaches. The post From Discovery to Development in Emerging Modalities appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
From Discovery to Development in Emerging Modalities. ProBio is building flexible platforms for multispecific antibodies, ADCs, and other advanced therapeutic approaches. The post From Discovery to Development in Emerging Modalities appeared first on GEN - Genetic Engineering and Biotechnology News .
TL;DR:
The post From Discovery to Development in Emerging Modalities appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 1, 10:55
Corning Advances the Organoid Revolution
As FDA support for NAMs accelerates, Corning is helping researchers standardize, scale, and automate organoid science. The post Corning Advances the Organoid Revolution appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Corning Advances the Organoid Revolution. As FDA support for NAMs accelerates, Corning is helping researchers standardize, scale, and automate organoid science. The post Corning Advances the Organoid Revolution appeared first on GEN - Genetic Engineering and Biotechnology News .
TL;DR:
The post Corning Advances the Organoid Revolution appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 1, 10:54
Evaluating CNS Anti-inflammatory Therapies with Human Brain Organoids
Inflammatory pathways involving microglia, astrocytes, and cytokine signaling are widely implicated in disorders including Alzheimer’s disease, Parkinson’s disease, ALS, multiple sclerosis, and traumatic brain injury. Yet despite significant investment in anti-inflammatory therapies, clinical success has remained limited. The post Evaluating CNS Anti-inflammatory Therapies with Human Brain Organoids appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Inflammatory pathways involving microglia, astrocytes, and cytokine signaling are widely implicated in disorders including Alzheimer’s disease, Parkinson’s disease, ALS, multiple sclerosis, and traumatic brain injury. Yet despite significant investment in anti-inflammatory therapies, clinical success has remained limited.
TL;DR:
The post Evaluating CNS Anti-inflammatory Therapies with Human Brain Organoids appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 1, 10:53
Soon…the First Organ-on-a-Chip Qualified Drug Development Tool
Sponsored content brought to you by Historical data indicate that animal models are not ideal for the determination of the efficacy and safety of human therapeutics. Ninety percent of drugs that pass […] The post Soon…the First Organ-on-a-Chip Qualified Drug Development Tool appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Soon…the First Organ-on-a-Chip Qualified Drug Development Tool. Sponsored content brought to you by Historical data indicate that animal models are not ideal for the determination of the efficacy and safety of human therapeutics.
TL;DR:
Ninety percent of drugs that pass […] The post Soon…the First Organ-on-a-Chip Qualified Drug Development Tool appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 1, 10:52
Spatial Atlasing: Why Sensitivity Is the Real Frontier
Throughput is no longer the bottleneck. Sensitivity is. A platform that captures only a fraction of transcripts per cell fails to detect lower-abundance populations that define an atlas’s resolution and utility. The post Spatial Atlasing: Why Sensitivity Is the Real Frontier appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Throughput is no longer the bottleneck. A platform that captures only a fraction of transcripts per cell fails to detect lower-abundance populations that define an atlas’s resolution and utility. The post Spatial Atlasing: Why Sensitivity Is the Real Frontier appeared first on GEN - Genetic Engineering and Biotechnology News .
TL;DR:
The post Spatial Atlasing: Why Sensitivity Is the Real Frontier appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 1, 10:51
ProPure™ Endotoxin-Free Proteins for Reliable Cancer Research
In discovery and preclinical studies, endotoxins are silent disruptors of animal immunization, sensitive biological assays, and toxicity assessments, compromising results and safety evaluations. Endotoxin-free recombinant proteins are therefore essential for generating reliable research data and successful development of next-generation cancer therapeutics. The post ProPure™ Endotoxin-Free Proteins for Reliable Cancer Research appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
In discovery and preclinical studies, endotoxins are silent disruptors of animal immunization, sensitive biological assays, and toxicity assessments, compromising results and safety evaluations. Endotoxin-free recombinant proteins are therefore essential for generating reliable research data and successful development of next-generation cancer therapeutics.
TL;DR:
The post ProPure™ Endotoxin-Free Proteins for Reliable Cancer Research appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
Jun 1, 10:50
Measuring Direct, Bystander, and Off-Target ADC Killing with the HiBiT TCK Platform
Promega’s nonlytic, bioluminescent bioassay platform that distinguishes bystander from direct cytotoxicity in a single co-culture experiment. The post Measuring Direct, Bystander, and Off-Target ADC Killing with the HiBiT TCK Platform appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Measuring Direct, Bystander, and Off-Target ADC Killing with the HiBiT TCK Platform. Promega’s nonlytic, bioluminescent bioassay platform that distinguishes bystander from direct cytotoxicity in a single co-culture experiment.
TL;DR:
The post Measuring Direct, Bystander, and Off-Target ADC Killing with the HiBiT TCK Platform appeared first on GEN - Genetic Engineering and Biotechnology News .
Endpoints
Jun 1, 10:43
Lilly licenses GLP-2 asset from Korean biotech Hanmi for $75M upfront
Eli Lilly, which has made billions off the success of its GLP-1 drugs, is now making a play for GLP-2s through a licensing deal with Hanmi. The Indianapolis drugmaker will pay $75 million upfront in ...
More:
Lilly licenses GLP-2 asset from Korean biotech Hanmi for $75M upfront. Eli Lilly, which has made billions off the success of its GLP-1 drugs, is now making a play for GLP-2s through a licensing deal with Hanmi. The Indianapolis drugmaker will pay $75 million upfront in ...
TL;DR:
Eli Lilly, which has made billions off the success of its GLP-1 drugs, is now making a play for GLP-2s through a licensing deal with Hanmi.
Endpoints
Jun 1, 10:19
#ASCO26: Erleada succeeds in early-stage prostate cancer study, but questions remain
CHICAGO — As part of a hormone therapy regimen for prostate cancer, J&J’s Erleada cut the risk of metastasis or death by 20% when given around surgery, researchers reported Sunday. Treatment with the drug before ...
TL;DR:
CHICAGO — As part of a hormone therapy regimen for prostate cancer, J&J’s Erleada cut the risk of metastasis or death by 20% when given around surgery, researchers reported Sunday.
Fiercebiotech
Jun 1, 07:30
Lilly pens $1.2B deal for Hanmi’s GLP-2 drug being aimed at short bowel syndrome
Eli Lilly has expanded its glucagon-like peptide portfolio in an intriguing direction by licensing a phase 2-stage GLP-2 agonist from Hanmi Pharm.
More:
Lilly pens $1.2B deal for Hanmi’s GLP-2 drug being aimed at short bowel syndrome. Eli Lilly has expanded its glucagon-like peptide portfolio in an intriguing direction by licensing a phase 2-stage GLP-2 agonist from Hanmi Pharm.
TL;DR:
Eli Lilly has expanded its glucagon-like peptide portfolio in an intriguing direction by licensing a phase 2-stage GLP-2 agonist from Hanmi Pharm.
Endpoints
Jun 1, 06:58
Oculis’ eye drops for diabetic macular edema flunk Phase 3 test
Oculis saw its stock plummet after reporting that its investigational eye drops for diabetic macular edema (DME) did not succeed in a pair of Phase 3 trials. After a year, its eye drop called OCS-01 ...
More:
Oculis saw its stock plummet after reporting that its investigational eye drops for diabetic macular edema (DME) did not succeed in a pair of Phase 3 trials. After a year, its eye drop called OCS-01 ...
TL;DR:
Oculis saw its stock plummet after reporting that its investigational eye drops for diabetic macular edema (DME) did not succeed in a pair of Phase 3 trials.
Genengnews
Jun 1, 00:58
StockWatch: Agilent Shares Jump on Better than Expected Quarterly Results
Agilent shares surged 17% from $115.79 to $135.42 Thursday, the first trading day after the tools giant announced better than expected results for the second quarter of its 2026 fiscal year ending April 30 (Agilent operates on a fiscal year that ends October 31). That was the best one-day performance since November 19, 2002, when the stock ballooned 16% to $134.50. The post StockWatch: Agilent Shares Jump on Better than Expected Quarterly Results appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
StockWatch: Agilent Shares Jump on Better than Expected Quarterly Results. Agilent shares surged 17% from $115.79 to $135.42 Thursday, the first trading day after the tools giant announced better than expected results for the second quarter of its 2026 fiscal year ending April 30 (Agilent operates on a fiscal year that ends October 31).
TL;DR:
The post StockWatch: Agilent Shares Jump on Better than Expected Quarterly Results appeared first on GEN - Genetic Engineering and Biotechnology News .
Endpoints
May 31, 12:06
#ASCO26: Yes, Revolution Medicine's pancreatic cancer data is that good
CHICAGO — When oncologist Brian Wolpin saw the positive results from Revolution Medicines' pivotal pancreatic cancer study for the first time, he was rendered speechless, he told Endpoints News. “Honestly, I just sort of stared at ...
More:
#ASCO26: Yes, Revolution Medicine's pancreatic cancer data is that good. CHICAGO — When oncologist Brian Wolpin saw the positive results from Revolution Medicines' pivotal pancreatic cancer study for the first time, he was rendered speechless, he told Endpoints News. “Honestly, I just sort of stared at ...
TL;DR:
CHICAGO — When oncologist Brian Wolpin saw the positive results from Revolution Medicines' pivotal pancreatic cancer study for the first time, he was rendered speechless, he told Endpoints News.
Endpoints
May 31, 12:00
#ASCO26: Summit, Akeso drug reduces death by 34% in China lung cancer study
CHICAGO — The leading drug in biopharma's hottest immunotherapy race reduced the risk of death by 34% in previously untreated Chinese lung cancer patients, compared to standard immunotherapy plus chemotherapy. The results, released in a ...
TL;DR:
CHICAGO — The leading drug in biopharma's hottest immunotherapy race reduced the risk of death by 34% in previously untreated Chinese lung cancer patients, compared to standard immunotherapy plus chemotherapy.
Fiercebiotech
May 31, 11:06
ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout
Kelonia Therapeutics has shared the largest slice of data yet for an in vivo CAR-T, helping to justify the $3.2 billion price tag that Eli Lilly recently paid to buy the Boston biotech.
TL;DR:
Kelonia Therapeutics has shared the largest slice of data yet for an in vivo CAR-T, helping to justify the $3.2 billion price tag that Eli Lilly recently paid to buy the Boston biotech.
Fiercebiotech
May 31, 11:06
ASCO: Revolution Medicines confident in RAS leadership as rivals square up
This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year. But even as competitors swirl, RevMed is confident that it can maintain the leadership position it has worked so hard to obtain.
More:
This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year. But even as competitors swirl, RevMed is confident that it can maintain the leadership position it has worked so hard to obtain.
TL;DR:
This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year.
Fiercebiotech
May 31, 11:06
ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
Although the first-in-class PD-1xVEGF bispecific didn’t disappoint on its overall survival headline message, detailed results from ivonescimab’s chemo-combo readout in first-line lung cancer are being picked apart by a critical pair of eyes.
TL;DR:
Although the first-in-class PD-1xVEGF bispecific didn’t disappoint on its overall survival headline message, detailed results from ivonescimab’s chemo-combo readout in first-line lung cancer are being picked apart by a critical pair of eyes.
Endpoints
May 31, 00:15
#ASCO26: Personalized cancer vaccines may help brain cancer patients live longer
Personalized cancer vaccines might make notoriously deadly brain cancers more susceptible to immunotherapy and possibly prolong survival for some patients, according to new research from the Dana-Farber Cancer Institute. The vaccines are ...
TL;DR:
Personalized cancer vaccines might make notoriously deadly brain cancers more susceptible to immunotherapy and possibly prolong survival for some patients, according to new research from the Dana-Farber Cancer Institute.
Endpoints
May 30, 23:59
#ASCO26: Grail’s cancer blood test isn’t ready for widespread use, experts say
Grail's blood test, which it has pitched as a way to spot a variety of cancers early in their growth, still isn't ready to be used as a regular screening tool, experts not involved with ...
TL;DR:
Grail's blood test, which it has pitched as a way to spot a variety of cancers early in their growth, still isn't ready to be used as a regular screening tool, experts not involved with ...
Fiercebiotech
May 30, 19:07
In next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach
In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard oncology endpoint—in their first-line non-small cell lung cancer clinical trials.
TL;DR:
In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard oncology endpoint—in their first-line non-small cell lung cancer clinical trials.
Statnews
May 30, 13:25
STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
TL;DR:
CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
Fiercebiotech
May 30, 12:40
ASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’
The German biotech shared updated data from a phase 1 study of the antibody-drug conjugate TUB-040, the star behind Gilead’s decision to buy the company for $3.15 billion upfront earlier this year.
TL;DR:
The German biotech shared updated data from a phase 1 study of the antibody-drug conjugate TUB-040, the star behind Gilead’s decision to buy the company for $3.15 billion upfront earlier this year.
Endpoints
May 30, 10:00
Can AI do scientific research?; The 'magic bullet' search has faded in immunotherapy; and more
Welcome back to Endpoints Weekly! We’ve got a team of reporters on the ground in Chicago this weekend for ASCO, including my fellow Weekly co-author Max Gelman. If you haven’t already, check out Max’s story ...
More:
Can AI do scientific research?; The 'magic bullet' search has faded in immunotherapy; and more . We’ve got a team of reporters on the ground in Chicago this weekend for ASCO, including my fellow Weekly co-author Max Gelman. If you haven’t already, check out Max’s story ...
TL;DR:
Welcome back to Endpoints Weekly!
Statnews
May 30, 10:00
STAT+: As Ebola outbreak grows, Trump administration veers from previous government playbook
Trump officials are disregarding the Biden administration's detailed pandemic plans in favor of their own strategy.
More:
STAT+: As Ebola outbreak grows, Trump administration veers from previous government playbook. Trump officials are disregarding the Biden administration's detailed pandemic plans in favor of their own strategy.
TL;DR:
Trump officials are disregarding the Biden administration's detailed pandemic plans in favor of their own strategy.
Genengnews
May 29, 19:25
Pfizer, Innovent Ink Up-to-$10.5B+ Cancer Treatment Collaboration
Pfizer and Innovent Biologics will partner to research and develop 12 early-stage and de novo antibodies and antibody-drug conjugates (ADCs) designed to treat various cancers, through a collaboration that could generate up to $10.5 billion for the Chinese biotech. The post Pfizer, Innovent Ink Up-to-$10.5B+ Cancer Treatment Collaboration appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Pfizer, Innovent Ink Up-to-$10.5B+ Cancer Treatment Collaboration. Pfizer and Innovent Biologics will partner to research and develop 12 early-stage and de novo antibodies and antibody-drug conjugates (ADCs) designed to treat various cancers, through a collaboration that could generate up to $10.5 billion for the Chinese biotech. The post Pfizer, Innovent Ink Up-to-$10.
TL;DR:
The post Pfizer, Innovent Ink Up-to-$10.5B+ Cancer Treatment Collaboration appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
May 29, 17:50
AI-Powered Pan-Cancer Map Reveals Tertiary Lymphoid Structures
Researchers developed a spatial atlas of tertiary lymphoid structures across multiple cancer types, revealing how key features vary across tumor types and may influence patient outcomes. The post AI-Powered Pan-Cancer Map Reveals Tertiary Lymphoid Structures appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
AI-Powered Pan-Cancer Map Reveals Tertiary Lymphoid Structures. Researchers developed a spatial atlas of tertiary lymphoid structures across multiple cancer types, revealing how key features vary across tumor types and may influence patient outcomes.
TL;DR:
The post AI-Powered Pan-Cancer Map Reveals Tertiary Lymphoid Structures appeared first on GEN - Genetic Engineering and Biotechnology News .
Endpoints
May 29, 17:30
Next FDA user fee deal is under review at the White House
The White House is examining a deal recently reached by the FDA and the biopharma industry that sets the prescription drug user fees that the sector will pay the agency from 2028 through 2032, sources ...
TL;DR:
The White House is examining a deal recently reached by the FDA and the biopharma industry that sets the prescription drug user fees that the sector will pay the agency from 2028 through 2032, sources ...
Endpoints
May 29, 17:23
Post-Hoc: Lilly gets more secretive and hides Phase 1 pipeline
Eli Lilly is getting more opaque as it gets bigger. Earlier this year, the drugmaker stopped disclosing its early-stage pipeline work. Its Phase 1 projects vanished from the company’s earnings presentation and were pulled from ...
More:
Post-Hoc: Lilly gets more secretive and hides Phase 1 pipeline. Eli Lilly is getting more opaque as it gets bigger. Its Phase 1 projects vanished from the company’s earnings presentation and were pulled from ...
TL;DR:
Eli Lilly is getting more opaque as it gets bigger.
Genengnews
May 29, 17:23
Antibiotic Design Strategy Overcomes Efflux-Mediated Resistance in Preclinical Study
Researchers developed a strategy for chemically redesigning antibiotics to be less easily ejected from the cells by bacterial efflux pumps, which could support the discovery of new antibiotics for drug-resistant infections, and revive antibiotics affected by efflux-mediated resistance. The post Antibiotic Design Strategy Overcomes Efflux-Mediated Resistance in Preclinical Study appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Antibiotic Design Strategy Overcomes Efflux-Mediated Resistance in Preclinical Study. Researchers developed a strategy for chemically redesigning antibiotics to be less easily ejected from the cells by bacterial efflux pumps, which could support the discovery of new antibiotics for drug-resistant infections, and revive antibiotics affected by efflux-mediated resistance.
TL;DR:
The post Antibiotic Design Strategy Overcomes Efflux-Mediated Resistance in Preclinical Study appeared first on GEN - Genetic Engineering and Biotechnology News .
Fiercebiotech
May 29, 17:01
Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform
Nine years after wowing the audience at the American Society of Clinical Oncology annual meeting with a CAR-T candidate that would become Carvykti—now the world’s most successful cell therapy—Legend Biotech’s scientific founder Frank Fan, M.D., Ph.D., is returning to the spotlight with an entirely new playbook.
TL;DR:
Nine years after wowing the audience at the American Society of Clinical Oncology annual meeting with a CAR-T candidate that would become Carvykti—now the world’s most successful cell therapy—Legend Biotech’s scientific founder Frank Fan, M.D., Ph.D., is returning to the spotlight with an entirely new playbook.
Endpoints
May 29, 15:30
AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions
🔎 AstraZeneca narrows path for failed antibody: The company announced last summer that its monoclonal antibody anselamimab missed the primary endpoint in a pair of Phase 3 trials for patients with ...
TL;DR:
🔎 AstraZeneca narrows path for failed antibody: The company announced last summer that its monoclonal antibody anselamimab missed the primary endpoint in a pair of Phase 3 trials for patients with ...
Genengnews
May 29, 15:27
Illumina Announces MRD Kit Ahead of ASCO Meeting
Ahead of ASCO 2026, Illumina unveiled an early-access MRD research kit using whole-genome sequencing and DRAGEN analysis, enabling highly sensitive cancer monitoring workflows on NovaSeq X systems for broader clinical research adoption. The post Illumina Announces MRD Kit Ahead of ASCO Meeting appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Illumina Announces MRD Kit Ahead of ASCO Meeting. Ahead of ASCO 2026, Illumina unveiled an early-access MRD research kit using whole-genome sequencing and DRAGEN analysis, enabling highly sensitive cancer monitoring workflows on NovaSeq X systems for broader clinical research adoption.
TL;DR:
The post Illumina Announces MRD Kit Ahead of ASCO Meeting appeared first on GEN - Genetic Engineering and Biotechnology News .
Endpoints
May 29, 15:07
Replimune will again submit its melanoma drug for approval
Third time’s the charm? Replimune announced Friday that it will submit its advanced melanoma drug RP1 for FDA review after two prior rejections. It said it has had new discussions with ...
More:
Third time’s the charm? Replimune announced Friday that it will submit its advanced melanoma drug RP1 for FDA review after two prior rejections. It said it has had new discussions with ...
TL;DR:
Replimune announced Friday that it will submit its advanced melanoma drug RP1 for FDA review after two prior rejections.
Genengnews
May 29, 15:00
Neuronal Protein Tracing Reveals How the Brain Routes Its Waste
A new neuronal protein‑tracing method maps how waste leaves the brain through distinct, region‑specific routes. The approach shows how inflammation and Alzheimer’s derail normal clearance pathways. The post Neuronal Protein Tracing Reveals How the Brain Routes Its Waste appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
A new neuronal protein‑tracing method maps how waste leaves the brain through distinct, region‑specific routes. The approach shows how inflammation and Alzheimer’s derail normal clearance pathways. The post Neuronal Protein Tracing Reveals How the Brain Routes Its Waste appeared first on GEN - Genetic Engineering and Biotechnology News .
TL;DR:
The post Neuronal Protein Tracing Reveals How the Brain Routes Its Waste appeared first on GEN - Genetic Engineering and Biotechnology News .
Statnews
May 29, 14:59
Kenya court suspends U.S. plan for Ebola quarantine facility for Americans
A court in Kenya on Friday suspended a U.S. plan to establish a quarantine facility for Americans exposed to a rare type of Ebola virus spreading in northeastern Congo.
More:
A court in Kenya on Friday suspended a U.S. plan to establish a quarantine facility for Americans exposed to a rare type of Ebola virus spreading in northeastern Congo.
TL;DR:
plan to establish a quarantine facility for Americans exposed to a rare type of Ebola virus spreading in northeastern Congo.
Endpoints
May 29, 14:50
Agios ends development of tebapivat in low-risk MDS following subpar results
Agios Pharmaceuticals has said it will stop developing its rare blood disorder drug for certain patients with myelodysplastic syndromes (MDS) due to disappointing Phase 2b data. The biotech’s pyruvate kinase activator, known as tebapivat, did ...
More:
Agios ends development of tebapivat in low-risk MDS following subpar results. Agios Pharmaceuticals has said it will stop developing its rare blood disorder drug for certain patients with myelodysplastic syndromes (MDS) due to disappointing Phase 2b data. The biotech’s pyruvate kinase activator, known as tebapivat, did ...
TL;DR:
Agios Pharmaceuticals has said it will stop developing its rare blood disorder drug for certain patients with myelodysplastic syndromes (MDS) due to disappointing Phase 2b data.
Fiercebiotech
May 29, 13:19
AstraZeneca, after phase 3 miss, posts subgroup data behind pitch for rare disease approval
AstraZeneca has shared data it believes can rescue anselamimab from a phase 3 failure, linking the rare disease drug candidate to a 62% improvement in survival in a prespecified subgroup.
TL;DR:
AstraZeneca has shared data it believes can rescue anselamimab from a phase 3 failure, linking the rare disease drug candidate to a 62% improvement in survival in a prespecified subgroup.
Fiercebiotech
May 29, 12:16
Agios’ next-gen PK drug fails blood cancer study but sickle cell disease ambitions remain undimmed
Agios Pharmaceuticals’ next-gen pyruvate kinase (PK) activator has failed a phase 2 study in a group of rare blood cancers, although the biopharma is still holding out hope in sickle cell disease (SCD).
TL;DR:
Agios Pharmaceuticals’ next-gen pyruvate kinase (PK) activator has failed a phase 2 study in a group of rare blood cancers, although the biopharma is still holding out hope in sickle cell disease (SCD).
Fiercebiotech
May 29, 12:10
Boston, China and the future of biotech
Senior Writer Darren Incorvaia talks with industry leaders and experts from Flagship Pioneering, MassBio and PassKey about funding pressures, AI, China's biotech ecosystem and what's next for drug development.
TL;DR:
Senior Writer Darren Incorvaia talks with industry leaders and experts from Flagship Pioneering, MassBio and PassKey about funding pressures, AI, China's biotech ecosystem and what's next for drug development.
Genengnews
May 29, 12:00
Bonito Biosciences and DaltonTx Collaborate on Precision Delivery for Oligotherapeutics
By combining closed-loop functional screening with AI-driven design, Bonito and DaltonTx aim to accelerate discovery of delivery systems that can reach tissues and cell types that have remained inaccessible to oligotherapeutics. The post Bonito Biosciences and DaltonTx Collaborate on Precision Delivery for Oligotherapeutics appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Bonito Biosciences and DaltonTx Collaborate on Precision Delivery for Oligotherapeutics. By combining closed-loop functional screening with AI-driven design, Bonito and DaltonTx aim to accelerate discovery of delivery systems that can reach tissues and cell types that have remained inaccessible to oligotherapeutics.
TL;DR:
The post Bonito Biosciences and DaltonTx Collaborate on Precision Delivery for Oligotherapeutics appeared first on GEN - Genetic Engineering and Biotechnology News .
Endpoints
May 29, 12:00
#ASCO26: Bristol Myers details Phase 3 trial win for Pomalyst successor
Bristol Myers Squibb’s next-gen multiple myeloma drug cut the risk of disease progression or death for certain patients by 52% when added on top of a combination treatment regimen. The New Jersey pharma company is ...
TL;DR:
Bristol Myers Squibb’s next-gen multiple myeloma drug cut the risk of disease progression or death for certain patients by 52% when added on top of a combination treatment regimen.
Fiercebiotech
May 29, 11:31
Chutes & Ladders—Allogene swaps in CMO as new chief exec
After more than eight years at the helm of off-the-shelf CAR-T company Allogene Therapeutics, co-founder David Chang, M.D., Ph.D., is stepping down so that Zachary Roberts, M.D., Ph.D., the biotech’s chief medical officer and head of R&D, can take his place starting June 30.
TL;DR:
After more than eight years at the helm of off-the-shelf CAR-T company Allogene Therapeutics, co-founder David Chang, M.D., Ph.D., is stepping down so that Zachary Roberts, M.D., Ph.D., the biotech’s chief medical officer and head of R&D, can take his place starting June 30.
Fiercebiotech
May 29, 11:02
ASCO: BMS’ CELMoD drug doubles PFS in ‘incredibly exciting’ ph. 3 myeloma study
Bristol Myers Squibb may have gone big in its pursuit of cereblon E3 ligase modulator (CELMoD) drugs, but today the pharma is standing tall.
TL;DR:
Bristol Myers Squibb may have gone big in its pursuit of cereblon E3 ligase modulator (CELMoD) drugs, but today the pharma is standing tall.
Fiercebiotech
May 29, 11:02
ASCO: Lilly debuts ‘strong’ bladder cancer data for potential Padcev challenger
Eli Lilly took to the stage at the American Society of Clinical Oncology meeting in Chicago to share early data for a new drug candidate that could, if all goes right, challenge the dominance of Pfizer and Astellas Pharma’s Padcev in bladder cancer.
TL;DR:
Eli Lilly took to the stage at the American Society of Clinical Oncology meeting in Chicago to share early data for a new drug candidate that could, if all goes right, challenge the dominance of Pfizer and Astellas Pharma’s Padcev in bladder cancer.
Endpoints
May 29, 11:00
David Chang to hand over the reins at Allogene; Ex-Esperion CEO gets started at Phlow
Longtime Allogene CEO David Chang will be stepping down at the end of June. Chang has served as the company’s CEO for the past eight years and will be succeeded by ...
More:
David Chang to hand over the reins at Allogene; Ex-Esperion CEO gets started at Phlow. Longtime Allogene CEO David Chang will be stepping down at the end of June. Chang has served as the company’s CEO for the past eight years and will be succeeded by ...
TL;DR:
Chang has served as the company’s CEO for the past eight years and will be succeeded by ...
Endpoints
May 29, 10:50
Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programs
On the eve of this year’s ASCO annual meeting, Pfizer said it is teaming up with China’s Innovent Biologics to advance a portfolio of 12 early-stage antibody-drug conjugates and multi-specific antibodies in a deal that ...
TL;DR:
On the eve of this year’s ASCO annual meeting, Pfizer said it is teaming up with China’s Innovent Biologics to advance a portfolio of 12 early-stage antibody-drug conjugates and multi-specific antibodies in a deal that ...
Fiercebiotech
May 29, 10:19
Gilead scraps lead arthritis drug from $405M MiroBio buyout in latest blow to BTLA agonist field
Gilead has abandoned work on the lead rheumatoid arthritis drug from its $405 million buyout of MiroBio in the latest blow to the BTLA agonist field.
TL;DR:
Gilead has abandoned work on the lead rheumatoid arthritis drug from its $405 million buyout of MiroBio in the latest blow to the BTLA agonist field.
Fiercebiotech
May 29, 07:31
Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by striking a broad pact that positions it to leverage China’s fast early development system.
TL;DR:
Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by striking a broad pact that positions it to leverage China’s fast early development system.
Fiercebiotech
May 28, 23:32
Biogen axes Denali-partnered Parkinson’s prospect after phase 2 flop
A phase 2b trial of Biogen and Denali Therapeutics’ Parkinson’s disease candidate has missed its primary endpoint, prompting the partners to end development in the idiopathic form of the condition.
More:
Biogen paid Denali $400 million in 2020 to partner on the LRRK2 program. The bet reflected evidence of LRRK2’s role in Parkinson’s, with researchers linking mutations that increase activity of the kinase to the aggregation of toxic proteins.
TL;DR:
A phase 2b trial of Biogen and Denali Therapeutics’ Parkinson’s disease candidate has missed its primary endpoint, prompting the partners to end development in the idiopathic form of the condition.
Fiercebiotech
May 28, 23:32
OSE turns up the heat on ovarian cancer with phase 2, Keytruda-supported win
OSE Immunotherapeutics has shared phase 2 data on its neo-epitope vaccine candidate and Keytruda in ovarian cancer, linking maintenance use of the combination to improvements over best supportive care.
More:
The researchers enrolled 185 recurrent ovarian cancer patients who either responded to platinum therapy or had stable disease after the treatment. Participants received best supportive care, OSE2101 as a monotherapy or the neo-epitope vaccine in combination with Merck & Co.’s Keytruda. Progression-free survival (PFS) on the OSE2101-Keytruda cocktail was 4.1 months, versus 2.
TL;DR:
OSE Immunotherapeutics has shared phase 2 data on its neo-epitope vaccine candidate and Keytruda in ovarian cancer, linking maintenance use of the combination to improvements over best supportive care.
Fiercebiotech
May 28, 23:32
Has Novartis’ T-Charge been overtaken by in vivo CAR-Ts? Execs argue there’s room for both
It’s been more than four years since Novartis shook up the CAR-T space with its T-Charge platform. But that’s a lifetime in the fast-moving world of cell therapies.
More:
Has Novartis’ T-Charge been overtaken by in vivo CAR-Ts? It’s been more than four years since Novartis shook up the CAR-T space with its T-Charge platform. But that’s a lifetime in the fast-moving world of cell therapies.
TL;DR:
It’s been more than four years since Novartis shook up the CAR-T space with its T-Charge platform.
Fiercebiotech
May 28, 23:32
Chutes & Ladders—Former FDA leader takes new biotech Turn
Stephen Hahn, M.D., who served as the commissioner of the FDA for just over a year during the first Trump administration, is taking his extensive regulatory expertise to Turn Therapeutics. As executive clinical and regulatory lead, Hahn will guide the regulatory strategy for GX-03, Turn’s topical eczema treatment that is currently in a phase 2 study.
More:
Stephen Hahn, M.D., who served as the commissioner of the FDA for just over a year during the first Trump administration, is taking his extensive regulatory expertise to Turn Therapeutics. As executive clinical and regulatory lead, Hahn will guide the regulatory strategy for GX-03, Turn’s topical eczema treatment that is currently in a phase 2 study.
TL;DR:
Stephen Hahn, M.D., who served as the commissioner of the FDA for just over a year during the first Trump administration, is taking his extensive regulatory expertise to Turn Therapeutics.
Fiercebiotech
May 28, 23:32
BioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions
Recorded at Fierce Biotech Week in Boston, this episode of “The Top Line” features a conversation with BioAge co-founder and CEO Kristen Fortney on aging biology, inflammation and why BioAge believes its oral NLRP3 inhibitor could have applications across multiple diseases.
TL;DR:
Recorded at Fierce Biotech Week in Boston, this episode of “The Top Line” features a conversation with BioAge co-founder and CEO Kristen Fortney on aging biology, inflammation and why BioAge believes its oral NLRP3 inhibitor could have applications across multiple diseases.
Fiercebiotech
May 28, 23:32
Lilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitors
Eli Lilly is laying the groundwork for a phase 2 trial of the lipid-lowering gene editor it picked up from Verve Therapeutics, with the candidate now showing strong and consistent cholesterol reductions after a higher dosing regimen.
More:
Lilly today shared that its one-time base editor VERVE-102, meant to permanently turn off the cholesterol-producing PCSK9 gene, slashed cholesterol by 62% in patients given the highest dose of one milligram per kilogram of body mass. This drop was sustained for up to 18 months, as were cholesterol reductions at lower dose levels previously reported by Verve.
TL;DR:
Eli Lilly is laying the groundwork for a phase 2 trial of the lipid-lowering gene editor it picked up from Verve Therapeutics, with the candidate now showing strong and consistent cholesterol reductions after a higher dosing regimen.
Fiercebiotech
May 28, 23:32
Facing looming Xtandi patent cliff, Astellas pins hopes on more deals while still cutting costs
Faced with a future of evaporating Xtandi sales, Astellas has set out ambitions to license fresh assets while also continuing to tighten its belt.
More:
The Japanese pharma may be expecting to rake in sales of 2.2 trillion yen ($13 billion) from Xtandi this year, but this is likely to be as good as it gets for the Pfizer-partnered blockbuster going forward. Astellas’ own slides show these prostate cancer sales withering away toward a “pipeline-led inflection point” in 2029.
TL;DR:
Faced with a future of evaporating Xtandi sales, Astellas has set out ambitions to license fresh assets while also continuing to tighten its belt.
Fiercebiotech
May 28, 23:32
Lilly inks deals to buy 3 vaccine developers for up to $3.8B as M&A spree continues
Eli Lilly has splashed up to $3.8 billion on an infectious disease pipeline, acquiring Curevo, LimmaTech Biologics and Vaccine Company to extend its shopping spree into viral and bacterial pathogen R&D.
More:
Securing the biotech will position Lilly to challenge GSK, which sells the shingles vaccine Shingrix. Curevo designed its shingles vaccine candidate, amezosvatein, to improve on the tolerability of Shingrix. Curevo used a next-generation synthetic adjuvant to improve tolerability.
TL;DR:
Eli Lilly has splashed up to $3.8 billion on an infectious disease pipeline, acquiring Curevo, LimmaTech Biologics and Vaccine Company to extend its shopping spree into viral and bacterial pathogen R&D.
Fiercebiotech
May 28, 23:32
Kura posts Krazati combo data on drug designed to unleash KRAS inhibitors’ potential
Kura Oncology has published early data on darlifarnib in combination with Bristol Myers Squibb’s Krazati, linking the drug candidate to response rates of up to 69% when given with the KRAS inhibitor.
More:
BMS’ Krazati and Amgen’s Lumakras, both of which inhibit KRAS G12C, were scientific breakthroughs, but the clinical data leave room for improvement. The biotech reported partial responses in four of six pancreatic ductal adenocarcinoma patients who received the combination. None of the patients had previously received a KRAS inhibitor such as Krazati or Lumakras.
TL;DR:
Kura Oncology has published early data on darlifarnib in combination with Bristol Myers Squibb’s Krazati, linking the drug candidate to response rates of up to 69% when given with the KRAS inhibitor.
Fiercebiotech
May 28, 23:32
Makary’s FDA reforms ‘continue to move forward’ despite leadership turmoil
As the FDA adjusts to life without Marty Makary, M.D., who resigned as commissioner two weeks ago, the numerous policy reforms he put in motion remain intact, including the controversial Commissioner’s National Priority Voucher (CNPV) program.
More:
Kyle Diamantas, head of the FDA’s food division, has stepped in as acting commissioner. Of all Makary's initiatives, the CNPV—under which certain drug candidates are granted expedited reviews through an opaque selection process—grabbed the most headlines.
TL;DR:
As the FDA adjusts to life without Marty Makary, M.D., who resigned as commissioner two weeks ago, the numerous policy reforms he put in motion remain intact, including the controversial Commissioner’s National Priority Voucher (CNPV) program.
Fiercebiotech
May 28, 23:32
As calls for COINS Act expansion grow, will new rules sweep up China biotech licensing?
Amid an intensifying debate over how Washington should counter China’s rapid ascent in the biotech sector, a growing chorus of policymakers and biotech insiders is urging the Treasury Department to expand the newly codified COINS Act to include biotechnology—a move that would extend outbound investment curbs to cross-border drug dealmaking.
More:
May 26, 2026 3:50pm Licensing deals China Congress U.S. “In an ideal world, it would apply to a lot of the biggest deals that these companies are going after,” she said. Kosloff’s recommendation has its supporters on Capitol Hill, at least among China hawks.
TL;DR:
Amid an intensifying debate over how Washington should counter China’s rapid ascent in the biotech sector, a growing chorus of policymakers and biotech insiders is urging the Treasury Department to expand the newly codified COINS Act to include biotechnology—a move that would extend outbound investment curbs to cross-border drug dealmaking.
Fiercebiotech
May 28, 23:32
Olympus pushes deeper into oncology with $270M BioProtect deal
Olympus is pushing deeper into prostate cancer care with the acquisition of BioProtect, an Israeli company whose biodegradable balloon spacer has been used in more than 11,000 procedures worldwide.
More:
May 26, 2026 3:57pm Olympus prostate cancer Radiation Oncology deal Olympus has signed a definitive agreement to acquire BioProtect for $270 million, adding biodegradable balloon spacer technology to its portfolio as the company broadens beyond its endoscopy stronghold into urology and cancer-treatment procedures.
TL;DR:
Olympus is pushing deeper into prostate cancer care with the acquisition of BioProtect, an Israeli company whose biodegradable balloon spacer has been used in more than 11,000 procedures worldwide.
Fiercebiotech
May 28, 23:32
FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote
The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed after an advisory committee voted against the breast cancer prospect.
More:
AstraZeneca filed for FDA approval of the oral SERD based on a phase 3 switching study. After the setback, AstraZeneca provided additional analyses requested by the FDA. The FDA has pushed back its ruling on whether to approve camizestrant while it reviews the analyses.
TL;DR:
The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed after an advisory committee voted against the breast cancer prospect.
Fiercebiotech
May 28, 23:32
Kardigan itching for IPO to fund late-stage cardiovascular pipeline
Kardigan may have only launched last year, but it seems the cardiovascular-focused biotech is already eyeing the public markets.
More:
May 27, 2026 4:57am Kardigan IPO biotech IPO cardiovascular Kardigan may have only launched last year, but it seems the cardiovascular-focused biotech is already eyeing the public markets. The Bay Area-based company is led by CEO Tassos Gianakakos, who previously headed up the cardiovascular disease biotech MyoKardia for seven years. Fellow MyoKardia veterans Jay Edelberg, M.D.
TL;DR:
Kardigan may have only launched last year, but it seems the cardiovascular-focused biotech is already eyeing the public markets.
Fiercebiotech
May 28, 23:32
Dexcom warns of stolen glucose monitors being sold by unauthorized dealers
Dexcom warned that some lots of its G7 wearable glucose monitors were stolen on their way to the scrapyard and were sold by a third-party vendor.
TL;DR:
Dexcom warned that some lots of its G7 wearable glucose monitors were stolen on their way to the scrapyard and were sold by a third-party vendor.
Fiercebiotech
May 28, 23:32
Apogee bags $1.3B Blackstone royalty funding deal to push eczema challenger into phase 3
Apogee Therapeutics has secured a promise of up to $1.3 billion in financing from Blackstone Life Sciences as the biotech gears up to take its anti-IL-13 antibody into phase 3.
More:
Of this tranche, Apogee can get $100 million straight away, with another $100 million available when phase 3 enrollment is completed and a further $200 million unlocked if the data from that trial is up to scratch. The remaining $400 million is held back by BXLS until zumilokibart can secure FDA approval, according to an April 27 release .
TL;DR:
Apogee Therapeutics has secured a promise of up to $1.3 billion in financing from Blackstone Life Sciences as the biotech gears up to take its anti-IL-13 antibody into phase 3.
Fiercebiotech
May 28, 23:32
Insulet issues voluntary correction for Omnipod devices in leaky insulin fault
Insulet has sent out a voluntary medical device correction notice for a series of its Omnipod devices amid a manufacturing fault that could lead to insulin leaking and not being fully delivered.
More:
This notice is for specific lots of Omnipod 5, Omnipod DASH, and Omnipod Insulin Management System (Omnipod Eros) Pods. In a Securities and Exchange Commission (SEC) filing , Insulet said it “expects to incur up to $50 million of costs associated with this correction in 2026.
TL;DR:
Insulet has sent out a voluntary medical device correction notice for a series of its Omnipod devices amid a manufacturing fault that could lead to insulin leaking and not being fully delivered.
Fiercebiotech
May 28, 23:32
D&D sees fibrosis improvements, MASH resolution after rolling dice on GLP-1 drug
D&D Pharmatech has linked its GLP-1/glucagon receptor agonist to improvements in liver health, keeping the Korean biotech in the hunt for a market already served by Novo Nordisk’s Wegovy.
More:
The new data cover the endpoints the FDA advises (PDF) sponsors to use in phase 3 MASH trials. At Week 48, half of the 16 patients taking 40 mg of zabopegdutide had at least a one-stage improvement in fibrosis and no worsening of MASH, compared with three of 19 people on placebo.
TL;DR:
D&D Pharmatech has linked its GLP-1/glucagon receptor agonist to improvements in liver health, keeping the Korean biotech in the hunt for a market already served by Novo Nordisk’s Wegovy.
Fiercebiotech
May 28, 23:32
Kordata Dynamics launches with neural-focused AI clinical trial model
Kordata Dynamics is emerging from stealth with the aim to redefine clinical trial execution by processing neural data while taking advantage of the FDA’s recent push for real-time clinical trials.
More:
Kordata is a spinout of neural digital health company BIOS Health and is launching with a pre-seed funding round from MAVRK Celestia Fund, Kern Venture Group and Digital Neural Infrastructure Holdings, according to a May 21 release .
TL;DR:
Kordata Dynamics is emerging from stealth with the aim to redefine clinical trial execution by processing neural data while taking advantage of the FDA’s recent push for real-time clinical trials.
Fiercebiotech
May 28, 23:32
GSK’s hepatitis B drug cures one-fifth of patients in ‘major step’ for pervasive disease
GSK is pulling back the curtain on the phase 3 success of its chronic hepatitis B drug bepirovirsen, revealing that nearly one-fifth of all treated patients across two trials were functionally cured of the virus.
More:
Though this cuts down viral numbers, the approach often stops short of eliminating the pathogen entirely. After treatment with bepirovirsen, however, 19% of patients achieved the strictly defined “functional cure” criteria.
TL;DR:
GSK is pulling back the curtain on the phase 3 success of its chronic hepatitis B drug bepirovirsen, revealing that nearly one-fifth of all treated patients across two trials were functionally cured of the virus.
Fiercebiotech
May 28, 23:32
Novartis ‘always looking’ for further ways to shuttle drugs to brain despite run of recent deals
Novartis may be launching an array of vehicles to shuttle drugs across the blood-brain barrier, but executives told Fierce the Swiss pharma is “always looking” for new ways to traverse this final frontier of neuroscience.
More:
One of the appeals of SciNeuro's monoclonal antibody is how it harnesses transferrin receptor (TFR) to drive drugs into the brain, according to Nazem Atassi, M.D., global development head of neurology and gene therapy at Novartis.
TL;DR:
Novartis may be launching an array of vehicles to shuttle drugs across the blood-brain barrier, but executives told Fierce the Swiss pharma is “always looking” for new ways to traverse this final frontier of neuroscience.
Fiercebiotech
May 28, 23:32
Human Longevity launches newco, teams with Insilico for AI-powered longevity research
Human Longevity, which is seeking to use biology and genomics to boost the human lifespan, has launched a new company called Human Life Foundation Models (HLFM) to help with its goal.
TL;DR:
Human Longevity, which is seeking to use biology and genomics to boost the human lifespan, has launched a new company called Human Life Foundation Models (HLFM) to help with its goal.
Fiercebiotech
May 28, 23:32
Hoth Therapeutics’ pivot to AI in space sees stock rocket after rebrand
Hoth Therapeutics’ search for salvation in the stars appears to have been rewarded by investors, as the company’s stock doubled after a pivot to powering AI in space.
More:
As Hoth, the biotech had been soldiering on with a neurokinin 1 receptor agonist for EGFR inhibitor-induced skin toxicities. But despite kicking off the year with phase 2 data that showed a reduction of acneiform rash, investors left Hoth’s stock bobbing around the $1 waterline this year.
TL;DR:
Hoth Therapeutics’ search for salvation in the stars appears to have been rewarded by investors, as the company’s stock doubled after a pivot to powering AI in space.
Fiercebiotech
May 28, 23:32
Icon ends internal accounting investigation, finds it overstated revenue in prior years
Irish CRO Icon has concluded its investigation into its accounting practices and restated its consolidated financials for 2023 and 2024.
More:
May 28, 2026 10:31am ICON CRO Earnings investigation Irish CRO Icon has closed the book on its investigation into its accounting practices and restated its consolidated financials for 2023 and 2024. According to the company’s fourth-quarter and full-year results , Icon’s revenue was overstated by 0.8% of total revenue in full-year 2023 and by 1.1% in full-year 2024.
TL;DR:
Irish CRO Icon has concluded its investigation into its accounting practices and restated its consolidated financials for 2023 and 2024.
Fiercebiotech
May 28, 23:32
FDA extends Beren’s rare disease review after info request, further stretching saga
The FDA has delayed its approval decision on Beren Therapeutics’ rare disease drug candidate, extending the asset’s long path toward the U.S. market.
More:
market. In February, the FDA accepted adrabetadex, an investigational cyclodextrin therapy, for priority review in Niemann-Pick disease type C. Needing time to review the updates and clarifications, the FDA has pushed the decision date back to Nov. Vtesse began the trial that year and was acquired for $200 million upfront by Sucampo in 2017.
TL;DR:
The FDA has delayed its approval decision on Beren Therapeutics’ rare disease drug candidate, extending the asset’s long path toward the U.S.
Genengnews
May 28, 18:50
Target for Aggressive Prostate Cancer Prevention Identified in Mice
Genetic or pharmacological inhibition of Sirtuin 1 prevents the growth of neuroendocrine prostate cancer tumors in mice, laying the groundwork for future clinical studies aimed at developing new treatments for NEPC in humans, according to a new study. The post Target for Aggressive Prostate Cancer Prevention Identified in Mice appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Genetic or pharmacological inhibition of Sirtuin 1 prevents the growth of neuroendocrine prostate cancer tumors in mice, laying the groundwork for future clinical studies aimed at developing new treatments for NEPC in humans, according to a new study.
TL;DR:
Genetic or pharmacological inhibition of Sirtuin 1 prevents the growth of neuroendocrine prostate cancer tumors in mice, laying the groundwork for future clinical studies aimed at developing new treatments for NEPC in humans, according to a new study.
Genengnews
May 28, 18:18
Targeting Metabolic Mechanism Restores Chemotherapy Sensitivity in Ovarian Cancer
Findings from a multi-institutional study suggest that disrupting a newly-identified metabolic process could weaken DNA repair in chemotherapy resistant cells, and restore sensitivity to DNA-damaging agents. The post Targeting Metabolic Mechanism Restores Chemotherapy Sensitivity in Ovarian Cancer appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Targeting Metabolic Mechanism Restores Chemotherapy Sensitivity in Ovarian Cancer. Findings from a multi-institutional study suggest that disrupting a newly-identified metabolic process could weaken DNA repair in chemotherapy resistant cells, and restore sensitivity to DNA-damaging agents.
TL;DR:
The post Targeting Metabolic Mechanism Restores Chemotherapy Sensitivity in Ovarian Cancer appeared first on GEN - Genetic Engineering and Biotechnology News .
Endpoints
May 28, 17:28
Lilly obesity meds Foundayo and Zepbound to gain CVS coverage
Eli Lilly’s flagship obesity medications will be included in CVS Caremark formularies, likely boosting sales in the most competitive commercial drug market. The company announced Thursday that its oral drug Foundayo ...
More:
Lilly obesity meds Foundayo and Zepbound to gain CVS coverage. Eli Lilly’s flagship obesity medications will be included in CVS Caremark formularies, likely boosting sales in the most competitive commercial drug market. The company announced Thursday that its oral drug Foundayo ...
TL;DR:
Eli Lilly’s flagship obesity medications will be included in CVS Caremark formularies, likely boosting sales in the most competitive commercial drug market.
Endpoints
May 28, 15:58
For wearables, it’s a GLP-1 world
We have two pieces of wearables-related news for you today, and (maybe unsurprisingly) GLP-1s came up in our conversations with both companies. First, Signos raised $20 million for its approach ...
More:
We have two pieces of wearables-related news for you today, and (maybe unsurprisingly) GLP-1s came up in our conversations with both companies. First, Signos raised $20 million for its approach ...
TL;DR:
We have two pieces of wearables-related news for you today, and (maybe unsurprisingly) GLP-1s came up in our conversations with both companies.
Endpoints
May 28, 14:51
ICON audit finds overstated revenue; Secretome and Psilera raise cash
👀 ICON’s audit probe is complete: The investigation found that ICON’s revenue was overstated by $65.3 million in 2023 (about 0.8% of its total revenue that year) and by $92.7 million in 2024 (1.1% of ...
More:
👀 ICON’s au­dit probe is com­plete: The in­ves­ti­ga­tion found that ICON’s rev­enue was over­stat­ed by $65.3 mil­lion in 2023 (about 0.8% of its to­tal rev­enue … Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
TL;DR:
👀 ICON’s audit probe is complete: The investigation found that ICON’s revenue was overstated by $65.3 million in 2023 (about 0.8% of its total revenue that year) and by $92.7 million in 2024 (1.1% of ...
Endpoints
May 28, 14:47
#ASCO26: After leaving Legend, Frank Fan is ready to showcase his next project
In 2022, Frank Fan moved more than 800 miles from Nanjing to Shenzhen, China, seeking a fresh start. He had abruptly left Legend Biotech, the CAR-T company he co-founded, just one month after the multiple ...
More:
#ASCO26: After leaving Legend, Frank Fan is ready to showcase his next project. In 2022, Frank Fan moved more than 800 miles from Nanjing to Shenzhen, China, seeking a fresh start. He had abruptly left Legend Biotech, the CAR-T company he co-founded, just one month after the multiple ...
TL;DR:
In 2022, Frank Fan moved more than 800 miles from Nanjing to Shenzhen, China, seeking a fresh start.
Endpoints
May 28, 13:54
Niowave’s $75M radioisotope facility; CordenPharma to buy AmbioPharm
Plus, news about Agilent’s earnings report: ☢️ Niowave’s radioisotope factory: The company has broken ground on a $75 million production facility in Lansing, MI, which will be used to manufacture and ...
More:
Plus, news about Ag­i­lent’s earn­ings re­port: ☢️ Niowave’s ra­dioiso­tope fac­to­ry: The com­pa­ny has bro­ken ground on a $75 mil­lion pro­duc­tion fa­cil­i­ty … Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
TL;DR:
Plus, news about Agilent’s earnings report: ☢️ Niowave’s radioisotope factory: The company has broken ground on a $75 million production facility in Lansing, MI, which will be used to manufacture and ...
Endpoints
May 28, 13:38
Charles River CEO says it likely won’t be the last manufacturer to break away from cell and gene therapy
Three months ago, Charles River Laboratories announced it would shed its manufacturing unit, which has a focus on cell and gene therapies. And, according to its CEO Birgit Girshick, other companies are likely considering doing ...
More:
Charles River CEO says it likely won’t be the last manufacturer to break away from cell and gene therapy. Three months ago, Charles River Laboratories announced it would shed its manufacturing unit, which has a focus on cell and gene therapies. And, according to its CEO Birgit Girshick, other companies are likely considering doing ...
TL;DR:
Three months ago, Charles River Laboratories announced it would shed its manufacturing unit, which has a focus on cell and gene therapies.
Endpoints
May 28, 12:30
China gene editing startup YolTech raises $70M to move CRISPR therapies forward
One of China’s most prolific gene editing companies has raised its biggest round of funding yet, ahead of plans to go public in Hong Kong. While most gene editing companies in the US trimmed their ...
More:
China gene editing startup YolTech raises $70M to move CRISPR therapies forward. One of China’s most prolific gene editing companies has raised its biggest round of funding yet, ahead of plans to go public in Hong Kong. While most gene editing companies in the US trimmed their ...
TL;DR:
While most gene editing companies in the US trimmed their ...
Endpoints
May 28, 12:00
Oura pushes deeper into healthcare services as part of new ring launch
Alongside the debut of Oura's smaller Ring 5, the wearables company on Thursday unveiled its plans to help users integrate health records and translate their ring’s findings into medical care. Oura has been building on ...
More:
Along­side the de­but of Oura’s small­er Ring 5, the wear­ables com­pa­ny on Thurs­day un­veiled its plans to help users in­te­grate health records and trans­late their … Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
TL;DR:
Alongside the debut of Oura's smaller Ring 5, the wearables company on Thursday unveiled its plans to help users integrate health records and translate their ring’s findings into medical care.
Endpoints
May 28, 11:20
AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase
AbbVie said the FDA has approved an antibody-drug conjugate it obtained as part of its $10.1 billion buyout of ImmunoGen for an ultra-rare but aggressive form of blood cancer. On Wednesday, the ...
More:
Ab­b­Vie said the FDA has ap­proved an an­ti­body-drug con­ju­gate it ob­tained as part of its $10.1 bil­lion buy­out of Im­muno­Gen for an … Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
TL;DR:
AbbVie said the FDA has approved an antibody-drug conjugate it obtained as part of its $10.1 billion buyout of ImmunoGen for an ultra-rare but aggressive form of blood cancer.
Genengnews
May 28, 09:03
PRINCE: A Small-Molecule Switch for Safer Gene Editing
Researchers developed PRINCE, a small-molecule-controlled CRISPR system enabling precise, long-term regulation of gene editing. Its compact version, Little Prince, showed therapeutic potential in mouse models of cholesterol disease and macular degeneration. The post PRINCE: A Small-Molecule Switch for Safer Gene Editing appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
PRINCE: A Small-Molecule Switch for Safer Gene Editing. Researchers developed PRINCE, a small-molecule-controlled CRISPR system enabling precise, long-term regulation of gene editing. The post PRINCE: A Small-Molecule Switch for Safer Gene Editing appeared first on GEN - Genetic Engineering and Biotechnology News .
TL;DR:
The post PRINCE: A Small-Molecule Switch for Safer Gene Editing appeared first on GEN - Genetic Engineering and Biotechnology News .
Endpoints
May 28, 08:30
GSK spells out positive Phase 3 data for hepatitis B drug it licensed from Ionis
GSK has shared detailed results from a pair of late-stage trials testing a chronic hepatitis B treatment originally developed by Ionis Pharmaceuticals, with regulatory reviews underway in four markets, including the US. Across two Phase ...
More:
GSK has shared de­tailed re­sults from a pair of late-stage tri­als test­ing a chron­ic he­pati­tis B treat­ment orig­i­nal­ly de­vel­oped by Io­n­is Phar­ma­ceu­ti­cals, with reg­u­la­to­ry re­views … Get free access to a limited number of articles, plus choose newsletters to get s…
TL;DR:
GSK has shared detailed results from a pair of late-stage trials testing a chronic hepatitis B treatment originally developed by Ionis Pharmaceuticals, with regulatory reviews underway in four markets, including the US.
Genengnews
May 27, 22:12
Sea Cucumber Tissues Demonstrate Natural Immortality in Seawater
Studies found that amputated tissue from a sea cucumber remains viable for years in natural seawater, providing evidence of diversifying cells, immune activity, and tissue reorganization, and potentially “compelling a redefinition of what it means for tissue to be alive.” The post Sea Cucumber Tissues Demonstrate Natural Immortality in Seawater appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Studies found that amputated tissue from a sea cucumber remains viable for years in natural seawater, providing evidence of diversifying cells, immune activity, and tissue reorganization, and potentially “compelling a redefinition of what it means for tissue to be alive.
TL;DR:
Studies found that amputated tissue from a sea cucumber remains viable for years in natural seawater, providing evidence of diversifying cells, immune activity, and tissue reorganization, and potentially “compelling a redefinition of what it means for tissue to be alive.” The post Sea Cucumber Tissues Demonstrate Natural Immortality in Seawater appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
May 27, 16:00
Automation and AI Will Drive Next-Gen CAR T Manufacturing
Industry leaders are now pursuing automation, AI-driven analytics, and in vivo engineering approaches designed to reduce costs, improve scalability, and accelerate patient access to personalized cell therapies for blood-cancer treatment. The post Automation and AI Will Drive Next-Gen CAR T Manufacturing appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Automation and AI Will Drive Next-Gen CAR T Manufacturing. Industry leaders are now pursuing automation, AI-driven analytics, and in vivo engineering approaches designed to reduce costs, improve scalability, and accelerate patient access to personalized cell therapies for blood-cancer treatment.
TL;DR:
The post Automation and AI Will Drive Next-Gen CAR T Manufacturing appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
May 27, 16:00
CGT Sector Opts for New Tech for Efficiency and Consistency
Cell and gene therapy developers are embracing innovative manufacturing technologies as they move toward commercialization. Digital systems are increasingly being used to address some of the unique challenges faced by the sector. The post CGT Sector Opts for New Tech for Efficiency and Consistency appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
CGT Sector Opts for New Tech for Efficiency and Consistency. Cell and gene therapy developers are embracing innovative manufacturing technologies as they move toward commercialization. The post CGT Sector Opts for New Tech for Efficiency and Consistency appeared first on GEN - Genetic Engineering and Biotechnology News .
TL;DR:
The post CGT Sector Opts for New Tech for Efficiency and Consistency appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
May 27, 16:00
Oligo Therapy Firms Moving Toward Less Expensive, High Production Methods
An explosion in new technologies for commercial oligonucleotide manufacturing is responding to the huge growth in drugs now reaching early and late clinical stages, as current techniques are inefficient. The post Oligo Therapy Firms Moving Toward Less Expensive, High Production Methods appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Oligo Therapy Firms Moving Toward Less Expensive, High Production Methods. An explosion in new technologies for commercial oligonucleotide manufacturing is responding to the huge growth in drugs now reaching early and late clinical stages, as current techniques are inefficient.
TL;DR:
The post Oligo Therapy Firms Moving Toward Less Expensive, High Production Methods appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
May 27, 16:00
Open-Source Up- and Downstream Modeling in a Unified Environment
The modular bioprocessing modeling platform developed by a European public-private partnership boasts modeling a variety of processes in the cloud. These integrated models require few programming skills and offer practical process development workflows. The post Open-Source Up- and Downstream Modeling in a Unified Environment appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Open-Source Up- and Downstream Modeling in a Unified Environment. The modular bioprocessing modeling platform developed by a European public-private partnership boasts modeling a variety of processes in the cloud. The post Open-Source Up- and Downstream Modeling in a Unified Environment appeared first on GEN - Genetic Engineering and Biotechnology News .
TL;DR:
The post Open-Source Up- and Downstream Modeling in a Unified Environment appeared first on GEN - Genetic Engineering and Biotechnology News .
Endpoints
May 27, 15:33
AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave
Plus news about Kailera, Alfasigma, Junshi and Kura. ⏰ FDA delays AstraZeneca’s camizestrant PDUFA date: The FDA has extended its PDUFA date for AstraZeneca’s breast cancer drug camizestrant, a few days ...
More:
AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave. Plus news about Kailera, Alfasigma, Junshi and Kura. ⏰ FDA delays AstraZeneca’s camizestrant PDUFA date: The FDA has extended its PDUFA date for AstraZeneca’s breast cancer drug camizestrant, a few days ...
TL;DR:
⏰ FDA delays AstraZeneca’s camizestrant PDUFA date: The FDA has extended its PDUFA date for AstraZeneca’s breast cancer drug camizestrant, a few days ...
Endpoints
May 27, 15:07
Apogee secures Blackstone capital to move Dupixent rival into Phase 3
The biggest question Apogee Therapeutics CEO Michael Henderson gets from investors? "These are big markets, this takes a lot of capital — are you just going to dilute us every time you have data?" Henderson said ...
More:
Apogee secures Blackstone capital to move Dupixent rival into Phase 3. The biggest question Apogee Therapeutics CEO Michael Henderson gets from investors? "These are big markets, this takes a lot of capital — are you just going to dilute us every time you have data?" Henderson said ...
TL;DR:
The biggest question Apogee Therapeutics CEO Michael Henderson gets from investors?
Endpoints
May 27, 13:55
WuXi Bio signs deal to manufacture Viridian's thyroid eye disease drug
WuXi Biologics has signed at least two new deals with notable US biotechs so far this year, signaling that the service provider continues to emerge from the shadow of the Biosecure Act. The Chinese CDRMO ...
More:
WuXi Bi­o­log­ics has signed at least two new deals with no­table US biotechs so far this year, sig­nal­ing that the ser­vice provider con­tin­ues to emerge … Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
TL;DR:
WuXi Biologics has signed at least two new deals with notable US biotechs so far this year, signaling that the service provider continues to emerge from the shadow of the Biosecure Act.
Endpoints
May 27, 13:53
#ASCO26: Cancer immunotherapy's magic bullet era is fading. Here's what's next
The two best-selling checkpoint inhibitors — Merck’s Keytruda and Bristol Myers Squibb’s Opdivo — are now approaching their patent cliffs. And the biopharma industry is coming to terms with the fact that it may not be able ...
More:
#ASCO26: Cancer immunotherapy's magic bullet era is fading. The two best-selling checkpoint inhibitors — Merck’s Keytruda and Bristol Myers Squibb’s Opdivo — are now approaching their patent cliffs. And the biopharma industry is coming to terms with the fact that it may not be able ...
TL;DR:
The two best-selling checkpoint inhibitors — Merck’s Keytruda and Bristol Myers Squibb’s Opdivo — are now approaching their patent cliffs.
Endpoints
May 27, 13:47
Biopharma Sentiment Index | Q2 2026
The latest BPSI shows significant improvements in biopharma conditions but raises questions about what comes next. Biopharma's mood isn't just running on hope anymore. The Biopharma Sentiment Index took another step forward in Q2. The ...
More:
The latest BPSI shows significant improvements in biopharma conditions but raises questions about what comes next. Biopharma's mood isn't just running on hope anymore. The Biopharma Sentiment Index took another step forward in Q2. The ...
TL;DR:
The latest BPSI shows significant improvements in biopharma conditions but raises questions about what comes next.
Endpoints
May 27, 13:00
Signos raises $20M as it eyes health plan, pharma relationships
Signos, a startup that aims to help people lose weight by understanding their blood sugar, raised $20 million as it looks beyond its direct-to-consumer roots to employers, health insurers and pharma companies. Palo Alto, CA-based ...
More:
Sig­nos, a start­up that aims to help peo­ple lose weight by un­der­stand­ing their blood sug­ar, raised $20 mil­lion as it looks be­yond its di­rect-to-con­sumer roots … Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
TL;DR:
Signos, a startup that aims to help people lose weight by understanding their blood sugar, raised $20 million as it looks beyond its direct-to-consumer roots to employers, health insurers and pharma companies.
Genengnews
May 27, 12:59
Biohub Releases Protein Biology World Model to Address Disease
The latest update to the ESM protein language model family has expanded capabilities in binder design and protein function mapping for therapeutic discovery. The release comes just seven months after Biohub recruited the team behind EvolutionaryScale. The post Biohub Releases Protein Biology World Model to Address Disease appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
Biohub Releases Protein Biology World Model to Address Disease. The latest update to the ESM protein language model family has expanded capabilities in binder design and protein function mapping for therapeutic discovery. The release comes just seven months after Biohub recruited the team behind EvolutionaryScale.
TL;DR:
The release comes just seven months after Biohub recruited the team behind EvolutionaryScale. The post Biohub Releases Protein Biology World Model to Address Disease appeared first on GEN - Genetic Engineering and Biotechnology News .
Genengnews
May 27, 12:00
WuXi’s Facility in China Receives Brazilian GMP Certification for Dengue Vaccine Manufacturing
WuXi Vaccines says the GMP certification of the company’s facility in China, its second certification from ANVISA, represents a pivotal step in advancing its dengue vaccine project with Brazil’s Instituto Butantan. The post WuXi’s Facility in China Receives Brazilian GMP Certification for Dengue Vaccine Manufacturing appeared first on GEN - Genetic Engineering and Biotechnology News .
More:
WuXi’s Facility in China Receives Brazilian GMP Certification for Dengue Vaccine Manufacturing. WuXi Vaccines says the GMP certification of the company’s facility in China, its second certification from ANVISA, represents a pivotal step in advancing its dengue vaccine project with Brazil’s Instituto Butantan.
TL;DR:
The post WuXi’s Facility in China Receives Brazilian GMP Certification for Dengue Vaccine Manufacturing appeared first on GEN - Genetic Engineering and Biotechnology News .
Endpoints
May 27, 10:45
Waypoint Bio raises $20M to run three CAR-T trials in China
New York City-based startup Waypoint Bio has raised $20 million in Series A financing to test multiple cell therapies in China, the company told Endpoints News. The move takes advantage of China's system for testing ...
More:
Waypoint Bio raises $20M to run three CAR-T trials in China. New York City-based startup Waypoint Bio has raised $20 million in Series A financing to test multiple cell therapies in China, the company told Endpoints News. The move takes advantage of China's system for testing ...
TL;DR:
New York City-based startup Waypoint Bio has raised $20 million in Series A financing to test multiple cell therapies in China, the company told Endpoints News.
Endpoints
May 27, 00:15
Kardigan readies Nasdaq IPO to back three cardio drugs
Heart health biotech Kardigan filed for a Nasdaq IPO as investor appetite heats up for shares of clinical-stage drug developers. The Princeton, NJ-based biotech plans to launch under the ticker symbol ...
More:
Kardigan readies Nasdaq IPO to back three cardio drugs. Heart health biotech Kardigan filed for a Nasdaq IPO as investor appetite heats up for shares of clinical-stage drug developers. The Princeton, NJ-based biotech plans to launch under the ticker symbol ...
TL;DR:
Heart health biotech Kardigan filed for a Nasdaq IPO as investor appetite heats up for shares of clinical-stage drug developers.
Endpoints
May 26, 17:39
Post-Hoc Live: Jeremy Levin on biotech's existential moment
We’ve spent the past year on Post-Hoc Live talking about existential moments for US biotech — the downturn, the recovery, China, MFN and more. On today's show, we were joined by one of the leading industry ...
More:
Post-Hoc Live: Jeremy Levin on biotech's existential moment. We’ve spent the past year on Post-Hoc Live talking about existential moments for US biotech — the downturn, the recovery, China, MFN and more. On today's show, we were joined by one of the leading industry ...
TL;DR:
We’ve spent the past year on Post-Hoc Live talking about existential moments for US biotech — the downturn, the recovery, China, MFN and more.
Endpoints
May 26, 17:16
Outlook says FDA will sign off on its version of Avastin for wet AMD
After three FDA rejections dating back to 2023, Outlook Therapeutics said the agency has reversed course regarding its reformulated version of Avastin for the eye condition known as wet AMD. "The FDA concluded that substantial ...
More:
Outlook says FDA will sign off on its version of Avastin for wet AMD. After three FDA rejections dating back to 2023, Outlook Therapeutics said the agency has reversed course regarding its reformulated version of Avastin for the eye condition known as wet AMD. "The FDA concluded that substantial ...
TL;DR:
"The FDA concluded that substantial ...
Endpoints
May 26, 15:06
Cartesian secures funding to 'accelerate' launch; Editas sells $125M in stock
💰 Cartesian Therapeutic’s $150M financing: The Maryland biotech secured $50 million in an initial tranche from K2 HealthVentures. The credit facility will help the company “accelerate” its commercial launch work in ...
More:
Cartesian secures funding to 'accelerate' launch; Editas sells $125M in stock. 💰 Cartesian Therapeutic’s $150M financing: The Maryland biotech secured $50 million in an initial tranche from K2 HealthVentures. The credit facility will help the company “accelerate” its commercial launch work in ...
TL;DR:
💰 Cartesian Therapeutic’s $150M financing: The Maryland biotech secured $50 million in an initial tranche from K2 HealthVentures.
Endpoints
May 26, 15:00
Can AI do scientific research? Billions chase hopes of superintelligence
RIO DE JANEIRO — Researchers at Lila Sciences were left scratching their heads over the lab results. They had built AI models to select mRNA molecules that express high levels of a desired protein. After ...
More:
Can AI do scientific research? RIO DE JANEIRO — Researchers at Lila Sciences were left scratching their heads over the lab results. They had built AI models to select mRNA molecules that express high levels of a desired protein.
TL;DR:
RIO DE JANEIRO — Researchers at Lila Sciences were left scratching their heads over the lab results.
Endpoints
May 26, 13:17
Exclusive: Protuoso gets $9.5M to build the next hub-and-spoke antibody developer
Variations on the hub-and-spoke model have blossomed in the drug development industry over the past few years — and a new antibody hub is entering the fray. Protuoso Biosciences collected a $9.5 million seed round from ...
More:
Exclusive: Protuoso gets $9.5M to build the next hub-and-spoke antibody developer. Variations on the hub-and-spoke model have blossomed in the drug development industry over the past few years — and a new antibody hub is entering the fray. Protuoso Biosciences collected a $9.5 million seed round from ...
TL;DR:
Variations on the hub-and-spoke model have blossomed in the drug development industry over the past few years — and a new antibody hub is entering the fray.
Endpoints
May 26, 11:20
Lilly to acquire three vaccine biotechs for up to $3.8B
Eli Lilly's dealmaking team must have a "that was easy" Staples button. The world's most valuable healthcare company and maker of the biggest-selling medicine globally is putting its cash to use for its eighth, ninth ...
More:
Lilly to acquire three vaccine biotechs for up to $3.8B. Eli Lilly's dealmaking team must have a "that was easy" Staples button. The world's most valuable healthcare company and maker of the biggest-selling medicine globally is putting its cash to use for its eighth, ninth ...
TL;DR:
Eli Lilly's dealmaking team must have a "that was easy" Staples button.
Nature Biotechnology
May 24, 00:16
CRISPR-Based Diagnostic Test Detects Any Pathogen in 15 Minutes
A CRISPR-powered diagnostic platform can detect any known viral or bacterial pathogen with 99.7% accuracy in 15 minutes, using a simple paper strip readout.
TL;DR:
A CRISPR-powered diagnostic platform can detect any known viral or bacterial pathogen with 99.7% accuracy in 15 minutes, using a simple paper strip readout.
The Lancet
May 1, 00:16
Gene Therapy Restores Hearing in Children Born Deaf
A single-dose AAV gene therapy restored functional hearing in 90% of children with congenital deafness caused by OTOF gene mutations.
TL;DR:
A single-dose AAV gene therapy restored functional hearing in 90% of children with congenital deafness caused by OTOF gene mutations.